



Go Green, Go Online!
JDDonline.com

As part of the JDD green initiative, starting in 2009, the author and subject indexes will be published exclusively online. In previous years these have been printed in the December Issue, but for your convenience and for environmental consciousness, the indexes will now be available electronically.

2010 SUBJECT INDEX

Letters after article titles refer to the following: **BC** = Brief Communication; **CR** = Case Reports; **CTR** = Clinical Trial Review; **FO** = Focus On; **IC** = Invited Commentary; **LCN** = Laser and Cosmetic News; **LR** = Literature Review; **NND** = No-Nonsense Dermoscopy; **NVR** = News, Views, and Reviews; **PP** = Pipeline Previews; **RR** = Resident Rounds; **SCF Update** = Skin Cancer Foundation Update; **SP** = Schools of Pharmacology; **WU** = Washington Update

- A**
- Abatacept**, safety and efficacy for chronic urticaria after inadequate response to antihistamine therapy (CTR), 86, 1159
- Abobotulinumtoxin A**. See also Botulinum toxin retrospective review of 500 patients treated with, 1081
- Abscesses**, cutaneous nontuberculous mycobacterial abscesses associated with insulin injections (CR), 1439
- ABT-874**. See Briakinumab
- AC-820 (nalfurafine HCl)**, safety and efficacy in subjects on hemodialysis with uremic pruritus (CTR), 82
- Acanthosis nigricans**, retinoids for palliative treatment of paraneoplastic acanthosis nigricans and oral florid papillomatosis (CR), 1151
- AccuView DV-5 Multi Imaging System** (PP), 418
- Acetyl hexapeptide-8 (AH8)**, in treatment of blepharospasm (CTR), 82
- Acitretin**, systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients and, 753
- Acne keloidalis nuchae**, Nd:YAG laser for (CTR), 577
- Acne vulgaris**
- AAADA calls for FDA to address Internet sales of isotretinoin and (PP), 282
- acne relapse rate of oral minocycline vs. oral minocycline combined with topical tretinoin, followed by topical tretinoin alone (CTR), 577, 727
- anti-inflammatory effects of topical dapsone for, 667
- antimicrobial efficacy of benzoyl peroxide/clindamycin phosphate gel vs. clindamycin phosphate/tretinoin gel for, 131
- apremilast for moderate-to-severe acne (CTR), 727, 1155, 1289, 1446
- avoiding antimicrobial resistance in treatment of, 519
- benzoyl peroxide-clindamycin combinations and skin hydration (PP), 80
- body image disturbance in patients with (RR), 725
- comparative study of tolerability of two combination therapies for (CTR), 187, 425
- comparison of safety and efficacy of ALA plus a 532 nm KTP laser vs. 532 nm KTP laser alone for facial acne, 229
- correction of atrophic acne scars with Artefil®, 1062
- current guide to laser and light-based therapies for, 614
- dapsone gel in combination with adapalene gel, benzoyl peroxide gel or moisturizer for, 33
- development of antimicrobial resistance due to antibiotic treatment of, 655
- drug-associated acne and acneiform eruptions, 627
- efficacy and safety of CD07223 gel in subjects with (CTR), 1446
- efficacy and safety of doxycycline and minocycline for, 1407
- efficacy and safety of fixed-dose adapalene-benzoyl peroxide combination gel in adolescents, 1395
- efficacy and safety of Visonac PDT for (CTR), 1155, 1289, 1446
- efficacy of benzoyl peroxide emollient foam and benzoyl peroxide wash for acne on the back, 622
- Epiduo® pediatric acne study (CTR), 1155
- Galderma receives approval for Differin® (adapalene) lotion 0.1% for (PP), 723
- irritation potential of tretinoin gel microsphere pump vs. adapalene plus benzoyl peroxide gel for, 998
- tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for, 805
- optimizing therapy with unique vehicles, s53 (May)
- PDT with MAL cream in patients with skin type V or VI with (CTR), 187, 425
- PDT with MAL without occlusion for, 1347
- in pregnancy (NVR), 1297
- properties of benzoyl peroxide and, 482
- psychosocial sequelae related to, s50 (May)
- two randomized clinical studies of adapalene lotion for, 639
- safety and efficacy of IDP-107 in patients with (CTR), 1446
- safety and efficacy of tazarotene cream and adapalene gel in, 549
- safety and efficacy of tazarotene foam 0.1% in subjects with facial acne (CTR), 187, 425, 1446
- safety of dapsone in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients, 532
- single-spot, 2940-nm Er:YAG dual-mode laser treatment of facial acne scars, 1341
- spironolactone and metformin in treatment of (NVR), 569
- topical tretinoin gel and acne in preadolescents (PP), 1033
- treatment of facial atrophic scars with Esthélics, 1507
- we are making progress with acne and rosacea (editorial), 603
- Acral lentiginous melanoma**, unilateral lichen planus pigmentosus mimicking (CR), 841
- Acrylic hydrogen suspended in hyaluronic acid**, histopathologic identification of dermal filler agents, 1072
- Actinic cheilitis**, PDT to treat actinic damage in patients with SCC of lip (CTR), 82, 1289
- Actinic keratoses (AK)**
- ALA-PDT vs. vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 82
- development of subacute cutaneous lupus erythematosus associated with use of imiquimod to treat AK (CR), 1022
- efficacy and safety study of 3.75% imiquimod cream following cryosurgery for, 1101
- etiologic, epidemiology and clinical presentation, 1125
- FDA 510(k) clearance of Fraxel re:store Dual Laser for (PP), 1552
- FDA approves Zyclara™ for (PP), 723
- past, present, and future, s45 (May)
- Perrigo announces FDA approval for imiquimod cream for (PP), 1552
- reduced number of AK with DNA repair enzyme creams, 1519
- topical perillyl alcohol in treating patients with sun damaged skin and AK (CTR), 82
- utilizing combination or sequential treatment with 5-fluorouracil cream and destructive treatments (CR), 864
- Acupuncture**, localized argyria secondary to (CR), 1019
- Acute cutaneous necrosis**, drug therapy for, 341
- Adalimumab**
- how and when to use biologics in psoriasis, s106 (August)
- use of biologic agents in pediatric psoriasis and, 975
- Adapalene**
- comparative study of tolerability of two combination therapies for acne (CTR), 187, 425

- dapsone gel in combination with adapalene gel, benzoyl peroxide gel or moisturizer for acne vulgaris, 33
- efficacy and safety of fixed-dose adapalene-benzoyl peroxide combination gel for acne in adolescents, 1395
- Epiduo® pediatric acne study (CTR), 1155
- Galderma receives approval for Differin® (adapalene) lotion 0.1% (PP), 723
- generic approval of adapalene cream 0.1% (PP), 1160
- irritation potential of tretinoin gel microsphere pump vs. adapalene plus benzoyl peroxide gel, 998
- properties of benzoyl peroxide, combined with, 482
- randomized clinical studies of adapalene lotion for acne, 639
- safety and efficacy of tazarotene cream and adapalene gel in facial acne vulgaris, 549
- trends in use for acne vulgaris, 519
- AEB071**, dose finding study assessing psoriasis area and severity index in patients with plaque psoriasis (CTR), 285
- Afamelanotide**, Clinuvel Pharmaceuticals gets FDA approval for light intolerance drug trial (PP), 723
- Aging skin**. See Cutaneous aging
- AIN457**, regimen finding study in psoriasis (CTR), 285
- Albaconazole**, study of effects of increasing doses of drug for nail fungus (CTR), 187, 425
- Alcoholics**, treatment of psoriasis in (CR), 405
- Alefacept**
how and when to use biologics in psoriasis and, s106 (August)
treatment of psoriasis for up to one year, 1491
use of biologic agents in pediatric psoriasis and, 975
- Alemtuzumab**, followed by peripheral stem cell transplantation in advanced mycosis fungoides/Sézary syndrome (CTR), 883
- Allium cepa, medical and surgical management of keloids and, 1249
- Aloe vera**, botanical approaches to alopecia and, 537
- Alopecia**
botanical approaches to, 537
hair growth in patients with alopecia areata totalis after treatment with simvastatin and ezetimibe (CR), 62
Hairmax Lasercomb for androgenetic alopecia in females (CTR), 1446
minoxidil for female pattern hair loss (CTR), 1446
new study implicates autoimmune mechanisms in alopecia areata (PP), 1160
pathogenesis, genetics and medical treatment of patterned hair loss, 1412
safety and pharmacokinetics of new formulation of bimatoprost in (CTR), 1446
spironolactone pills vs. minoxidil lotion in female pattern hair loss (CTR), 577
treatment of alopecia areata of scalp with intradermal injections of botulinum toxin (CTR), 82
treatment of androgenetic alopecia in females, 12 beam (CTR), 1446
- Altanax®**. See Retapamulin
- AMG 157**, safety study in healthy subjects and subjects with atopic dermatitis (CTR), 883, 1035, 1155, 1446
- Amineptine**, drug-associated acne and acneiform eruptions, 627
- Aminolevulinic acid (ALA)**
ALA-PDT for cutaneous pseudolymphoma (CR), 688
ALA-PDT vs. vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 82
comparison of safety and efficacy of ALA plus a 532 nm KTP laser vs. 532 nm KTP laser alone for facial acne, 229
PDT using ALA in treating patients with skin cancer (CTR), 82
PDT with MAL cream in patients with skin type V or VI with acne (CTR), 187, 425
- Ammonium lactate**, efficacy of Ultravate ointment in combination with Lac-Hydrin cream for psoriasis (CTR), 285, 577, 1035
- Anakira**, for atopic dermatitis (CTR), 1035, 1155, 1446
- Androgens and anabolic-androgenic drugs**, drug-associated acne and acneiform eruptions, 627
- Anesthetics, topical**
effect of lidocaine when mixed with large gel particle hyaluronic acid filler on tolerability and longevity, 1097
FDA approves Juvéderm® XC with lidocaine (PP), 418
pain with Radiesse® with lidocaine for nasolabial folds (CTR), 577
safety and efficacy of topical 4% lidocaine gel in unique drug delivery system, 1500
- Angioedema** (NVR), 1545
hereditary, FDA approval of ecallantide for (PP), 572
- Angioimmunoblastic T-cell lymphoma**, primary cutaneous (CR), 851
- Angiosarcoma**
bevacizumab for (CTR), 285
gemcitabine and docetaxel with or without bevacizumab in leiomyosarcoma, malignant fibrous histiocytoma and (CTR), 285
- Animal models**, ustekinumab effects on primate/human antigen-recall and humoral immune response functions, 677
- Anisotriazine**, sunscreen update: controversies, what's safe, what's next (NVR), 1451
- Annular leukocytoclastic vasculitis**, sorafenib-associated (CR), 697
- Anogenital warts**, Helix BioPharma and topical interferon alpha-2b for (PP), 723
- Anorexia nervosa**, dermatologic indicators of (NVR), 412
- Antiepileptic drugs**, postpubertal eruptive syringoma triggered with (CR), 707
- Antifungal drugs**
antifungal activity and nail permeation of innovative ciclopirox nail lacquer, 525
comparison of SUBA™-itraconazole with SPO-RANOX® for onychomycosis (CTR), 187, 285, 425
cutaneous fixed drug eruption to fluconazole (CR), 1025
efficacy and safety of iontophoretic application of terbinafine gel in onychomycosis (CTR), 577, 1155
efficacy of itraconazole in BCC (CTR), 883, 1035
fluconazole-associated Stevens-Johnson syndrome (CR), 1272
onychomycosis therapy, 1109
pharmacokinetics and safety of luliconazole solution in distal subungual onychomycosis (CTR), 577, 1155
safety and efficacy of NAB001 for onychomycosis of toenails (CTR), 1538
safety and efficacy of topical IDP-108 vs. vehicle in onychomycosis (CTR), 285, 577, 1538
- study of effects of increasing doses of drug for nail fungus (CTR), 187, 425
TDT 067 onychomycosis study (CTR), 1538
- Antihistamines**
safety and efficacy of abatacept for chronic urticaria after inadequate response to (CTR), 86, 1155
second-generation, for chronic idiopathic urticaria, 503
topical, efficacy for pruritus, 992
- Antihypertensive drugs**, oral lichenoid drug reaction associated with hypoglycemic drugs and (CR), 73
- Antimicrobial drugs**
acne relapse rate of oral minocycline vs. oral minocycline combined with topical tretinoin, followed by topical tretinoin alone (CTR), 577, 727
antibacterial effects of a chitosan-containing spray, 1237
antimicrobial efficacy of benzoyl peroxide/clindamycin phosphate gel vs. clindamycin phosphate/tretinoin gel for acne vulgaris, 131
avoiding antimicrobial resistance in treatment of acne vulgaris, 519
benzoyl peroxide-clindamycin combinations and skin hydration (PP), 80
changes in rosacea comorbidities and treatment utilization over time, 1402
comparative study of tolerability of two combination therapies for acne (CTR), 187, 425
development of antimicrobial resistance due to antibiotic treatment of acne, 655
efficacy and safety of doxycycline and minocycline for acne, 1407
efficacy of metronidazole in treatment of cutaneous and mucosal lichen planus, 1186
efficacy of topical azelaic acid gel plus oral doxycycline vs. metronidazole gel plus oral doxycycline in rosacea, 607
FDA Advisory Committee recommends approval of ceftaroline fosamil (PP), 1552
management of guttate psoriasis and pityriasis rosea in patients with evidence of group A streptococcal infection (CR), 241
Tamiflu®: what dermatologists need to know (NVR), 76
oregano-based ointment with antimicrobial activity against MRSA, 377
retapamulin in age of *S. aureus* resistance to, 1198
retapamulin vs. linezolid in treatment of SITL and impetigo due to MRSA (CTR), 82, 1538
safety and efficacy of CEM-102 vs. linezolid in bacterial skin infections (CTR), 1538
safety and efficacy of clindamycin and tretinoin gel for rosacea (CTR), 187, 285, 425, 1035, 1538
safety of topical doxycycline gel for adult diabetic lower extremity ulcers (CTR), 82
sales of Zeftera stopped in Canada (PP), 874
tigecycline linked to increased mortality risk (PP), 1455
TR-701 for bacterial skin infections (CTR), 1538
using off-patent antibiotics for MRSA (CTR), 1538
- Antioxidants**
controlled multi-center study evaluating the efficacy of Vivité Skin Care for photoaging of face, eye and mouth, 22
dose-dependent antioxidant function of resveratrol, 1523
efficacy and tolerance of novel phenolic antioxidant skin care system, 1480
N-acetylcysteine to reduce melanoma risk (PP), 183
oxidative damage, skin aging, antioxidants and a

- novel antioxidant rating system, 11
- Anti-tumor necrosis factor-(TNF) therapy**
atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab, 57
- cutaneous lupus erythematosus and (CR), 1283
- drug-associated acne and acneiform eruptions, 627
- efficacy and safety of adding methotrexate to etanercept in psoriasis (CTR), 82
- etanercept for chronic urticaria (CTR), 1155
- etanercept for familial pityriasis rubra pilaris (CR), 844
- etanercept for recalcitrant cicatricial pemphigoid (CR), 68
- etanercept in lichen planus (CTR), 187, 425, 577
- how and when to use biologics in psoriasis and, s106 (August)
- injectable biologic and U0279 combination therapy for psoriasis (CTR), 285
- long-term safety and efficacy of etanercept in psoriasis, 928
- prospective new biologic therapies for psoriasis and psoriatic arthritis, 947
- rapid improvement of pyoderma gangrenosum after infliximab treatment (CR), 702
- safety and effectiveness of etanercept for lichen planus of oral mucosa or skin (CTR), 577
- safety and effectiveness of etanercept for lichen planus or oral mucosa or skin (CTR), 883
- safety and efficacy of etanercept for discoid lupus erythematosus (CTR), 1538
- safety and efficacy of ustekinumab in psoriatic arthritis patients who have prior exposure to anti-TNF agents (CTR), 1155
- use in pediatric psoriasis, 975
- ustekinumab vs. etanercept for psoriasis (PP), 572
- Antiviral drugs**
EPB-348 for herpes zoster (CTR), 1035
- FV-100 vs. valacyclovir for herpes zoster (CTR), 1035
- Mylan receives approval for generic Valtrex® (PP), 1033
- safety and pharmacokinetics of famciclovir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 285
- Anxiety**, relaxation strategies for patients during dermatologic surgery, 795
- Apremilast**
in atopic or contact dermatitis (CTR), 187
- for lichen planus (CTR), 577, 883
- for moderate-to-severe acne (CTR), 727, 1155, 1289, 1446
- positive phase 2b clinical trial for psoriasis treatment (PP), 282
- for rosacea (CTR), 727, 1035, 1538
- safety study of clinical and immune effects in cutaneous lupus (CTR), 1538
- Arginine butyrate**, plus standard local therapy in patients with refractory sickle cell ulcers (CTR), 1289
- Argyria**, localized, secondary to acupuncture (CR), 1019
- Aripiprazole**, drug-associated acne and acneiform eruptions, 627
- Artefill®**, for correction of atrophic acne scars, 1062
- Arthritis**
pancreatitis, panniculitis and polyarthritis syndrome (CR), 1145
- psoriatic
adult onset, certolizumab pegol for (CTR), 1446
- atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57
- prospective new biologic therapies for psoriasis and, 947
- safety and efficacy of ustekinumab in patients who have prior exposure to anti-TNF agents (CTR), 1155
- Ascherson's syndrome**, drug therapy for, 341
- Asclera**. See Polidocanol
- ASP015K**, efficacy and safety in psoriasis (CTR), 1035, 1446
- Atacicept**, in generalized systemic lupus erythematosus (CTR), 1538
- Atopic dermatitis**
adherence and efficacy of desonide hydrogel for, 324
- anakinra for (CTR), 1035, 1155, 1446
- apremilast in contact dermatitis or (CTR), 187
- cost-effectiveness of tacrolimus ointment vs. pimecrolimus cream for, 372
- effect of pimecrolimus cream on cathelicidin levels in eczema (CTR), 883
- efficacy of triamcinolone 0.1% cream occluded with hydrogel patch vs. triamcinolone 0.1% cream without occlusion for (CTR), 883
- evidence-based review of coal tar preparations for, 1258
- management of pruritus with Xyzal in (CTR), 82
- mycophenolate mofetil for chronic dermatitis, 356
- nonsteroidal lamellar matrix cream containing palmytoyethanolamide for, 334
- pediatric indication for Locoid Lipocream® cream (PP), 80
- pediatric longitudinal evaluation of long-term safety of Protopic® for (CTR), 1446
- in pregnancy (NVR), 1297
- pruritus in, 488
- safety study of AMG 157 in healthy subjects and subjects with atopic dermatitis (CTR), 883, 1035, 1155, 1446
- topical vitamin B12 for children with (CTR), 1155, 1446
- treatment with concurrent Altanax® and topical low-potency corticosteroids vs. low-potency corticosteroid monotherapy (CTR), 883, 1035
- Azathioprine**, drug-associated acne and acneiform eruptions, 627
- Azelaic acid**
efficacy in psoriasis, 964
- efficacy of topical azelaic acid gel plus oral doxycycline vs. metronidazole gel plus oral doxycycline in rosacea, 607
- vs. hydroquinone in melasma (CTR), 727
- B**
Basal cell carcinoma (BCC)
BMS-833923 (XL139) in advanced or metastatic cancer (CTR), 883, 1035
- celecoxib inhibition of genetic BCC (PP), 418
- efficacy and safety of GDC-0449 in patients with advanced BCC (CTR), 85, 289
- efficacy of itraconazole in (CTR), 883, 1035
- efficacy of PDT for recurrent SCC and BCC, 122
- electronic brachytherapy for non-melanoma skin cancer (CTR), 1035
- flexible scalpel for minimally invasive and minimally scarring surgery for large scalp tumors, 1268
- fractional photothermolysis for depressed alar scar following Mohs micrographic surgery for (CR), 66
- multi-wavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented skin lesions (CTR), 1035
- of nasal pyramid, intralesional interferon alfa-2b for, 381
- patient with nevoid BCC syndrome treated successfully with PDT (CR), 167
- rapid wound re-epithelialization and BCC clearance after Mohs micrographic surgery with postoperative PDT (CR), 143
- rapid wound re-epithelialization and BCC clearance after Mohs surgery with postoperative PDT (RR), 878
- safety, local tolerability, pharmacokinetics, and pharmacodynamics of LDE225 on sporadic superficial skin BCC (CTR), 285, 883, 1035
- Behçet's disease**
multiple skin cancers in a patient on combination immunosuppressive therapy for (CR), 152
- thalidomide and analogues for, 814
- Benzoyl peroxide (BPO)**
antimicrobial efficacy of benzoyl peroxide/clindamycin phosphate gel vs. clindamycin phosphate/tretinoin gel for acne vulgaris, 131
- benzoyl peroxide-clindamycin combinations and skin hydration (PP), 80
- comparative study of tolerability of two combination therapies for acne (CTR), 187, 425
- dapsone gel in combination with adapalene gel, benzoyl peroxide gel or moisturizer for acne vulgaris, 33
- efficacy and safety of fixed-dose adapalene-benzoyl peroxide combination gel for acne in adolescents, 1395
- efficacy of benzoyl peroxide emollient foam and benzoyl peroxide wash for acne on back, 622
- Epiduo® pediatric acne study (CTR), 1155
- irritation potential of tretinoin gel microsphere pump vs. adapalene plus benzoyl peroxide gel, 998
- morning/morning and morning/evening regimens of tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for acne, 805
- optimizing acne therapy with unique vehicles, s53 (May)
- properties of, 482
- Benzyl alcohol lotion 5%**, for head lice (PP), 572
- Beta-blockers**
for chronic wound healing (CTR), 727
- drug-associated acne and acneiform eruptions, 627
- Betamethasone dipropionate**, safety and HPA axis effects of two-compound ointment containing calcipotriene/betamethasone dipropionate for psoriasis, 969
- Bevacizumab**
for angiosarcoma (CTR), 285
- gemcitabine and docetaxel with or without bevacizumab in leiomyosarcoma, malignant fibrous histiocytoma and angiosarcoma (CTR), 285
- Bexarotene**
development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome (CR), 1014
- systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients, 753
- BFH722**, safety and efficacy in psoriasis patients (CTR), 187, 425
- Bicillin L-A**, vs. placebo for psoriasis unresponsive to topical medications (CTR), 425
- Bimatoprost**
ophthalmic solution, in promoting eyebrow and eyelash hair growth in breast cancer patients (CTR), 82, 577
- safety and pharmacokinetics of new formulation of bimatoprost in alopecia (CTR), 1446

Biologics

Briakinumab and, S106 (August)
 How and when to use in psoriasis, S106 (August)
 Prospective new biologic therapies for psoriasis and psoriatic arthritis and, 947
 Use of biologic agents in pediatric psoriasis and, 975

Biomaterials

attaining predictable aesthetic results with dermal fillers, 458
 Belotero dermal filler close to FDA approval (PP), 1455
 calcium hydroxyapatite in nonsurgical aesthetic rejuvenation, 446
 collagen-glycosaminoglycan copolymer for severe chest keloids, 542
 correction of atrophic acne scars with Artefill®, 1062
 current and future botulinum neurotoxin type A preparations in aesthetics, 1065
 effect of lidocaine when mixed with large gel particle hyaluronic acid filler on tolerability and longevity, 1097
 efficacy of spray silicone in alteration of burn scar (CTR), 727
 Emervel Classic Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
 Emervel Deep Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
 evaluation of a liquid silicone gel on scar appearance after excisional surgery (CR), 856
 face and neck revitalization with platelet-rich plasma, 466
 failure of botulinum toxin treatment for localized vitiligo, 1092
 FDA approves Juvéderm® XC with lidocaine (PP), 418
 fillers for facial shaping, s129 (August)
 formulation composition of botulinum toxins in clinical use, 1085
 histopathologic identification of dermal filler agents, 1072
 hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for aesthetic rejuvenation therapy, 1135
 injection techniques for revolumization of perioral region with hyaluronic acid, 367
 localization and histology of injected hyaluronic acid in excised nasolabial fold tissue (CR), 399
 Mederma® for stretch marks (PP), 418
 minimally invasive techniques for periorbital rejuvenation, s118 (August)
 monophasic, cohesive-polydensified-matrix crosslinking-technology-based HA filler for facial lipatrophy in HIV-infected patients (CR), 690
 pain with Radiesse® with lidocaine for nasolabial folds (CTR), 577
 Restylane and Perlane in correction of peri-oral wrinkles (CTR), 187
 retrospective review of 500 patients treated with abobotulinumtoxinA, 1081
 SkinMedical launches new Rejuvenize Peel™ (PP), 418
 treatment of facial atrophic scars with Esthélics, 1507
 treatment of forehead/glabellar rhytide complex with combination botulinum toxin A and hyaluronic acid vs. botulinum toxin injection alone (CTR), 1538
 use of injectable poly-L-lactic acid in people of color, 451
 utilization of a new tissue expander in closure of large Mohs surgical defect (CR), 149

Bisocetrol, sunscreen update: controversies, what's safe, what's next (NVR), 1451
Blepharospasm, acetyl hexapeptide-8 (AH8) in treatment of (CTR), 82
Blue light therapy, current guide to laser and light-based therapies for acne, 614
BMS-833923 (XL139), in advanced or metastatic cancer (CTR), 883, 1035
Body contouring
 PureGraft™ System receives marketing clearance (PP), 723
 Zeltiq receives FDA clearance (PP), 1552
Body image disturbance, in patients with acne (RR), 725
Bone, osteoinvasive subungual melanoma (CR), 159
Botanical products
 for actinic keratoses, s45 (May)
 for alopecia, 537
 cosmeceuticals in clinical practice, s62 (May)
Botulinum toxin
 cost effectiveness for treatment of depression, 27
 current and future botulinum neurotoxin type A preparations in aesthetics, 1065
 expanding the use of neurotoxins in facial aesthetics, s7 (January)
 failure of treatment for localized vitiligo, 1092
 FDA approves Merz Pharmaceuticals' Xeomin® (PP), 1455
 formulation composition of botulinum toxins in clinical use, 1085
 hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for aesthetic rejuvenation therapy, 1135
 minimally invasive techniques for periorbital rejuvenation, s118 (August)
 practical applications of a new type of, s31 (March)
 for psoriasis (CTR), 82, 1035
 to reduce itch (PP), 282
 retrospective review of 500 patients treated with abobotulinumtoxinA, 1081
 treatment of alopecia areata of scalp with intradermal injections of (CTR), 82
 treatment of forehead/glabellar rhytide complex with combination botulinum toxin A and hyaluronic acid vs. botulinum toxin injection alone (CTR), 1538
Brachytherapy, electronic, for non-melanoma skin cancer (CTR), 1035
Breast surgery, safety and efficacy of EXC 001 to improve appearance of scars from (CTR), 728
Briakinumab
 See also Biologics
 for psoriasis and psoriatic arthritis, 947
 use in pediatric psoriasis, 975
Brown recluse spider bite, drug therapy for, 341
Bulimia nervosa, dermatologic indicators of (NVR), 412
Bullous skin disorders
 autoimmune, hematopoietic stem cell support in patients with (CTR), 1289
 efficacy and safety of omalizumab in bullous pemphigoid (CTR), 187, 425, 577, 1289
Bupropion, Stevens-Johnson syndrome with acute psoriatic exacerbation induced by (CR), 1010
Burn scars
 ablative fractional treatment of mature scars (CR), 389
 appearance after CO2 fractional laser treatment (CTR), 727
 CO2 fractional laser treatment of (CR), 173
 efficacy of spray silicone in alteration of (CTR),

727

Buruli ulcer, drug therapy for, 341

C

Calciphylaxis
 drug therapy for, 341
 warfarin-induced skin necrosis mimicking (CR), 859
Calcipotriene
 FDA approves Glenmark's calcipotriene ointment (PP), 723
 safety and HPA axis effects of two-compound ointment containing calcipotriene/betamethasone dipropionate for psoriasis, 969
Calcium dobesilate, combination therapy for rosacea (CTR), 187, 285, 425, 1538
Calcium hydroxyapatite
 fillers for facial shaping, s129 (August)
 histopathologic identification of dermal filler agents, 1072
 in nonsurgical aesthetic rejuvenation, 446
 pain with Radiesse® with lidocaine for nasolabial folds (CTR), 577
Capecitabine, increased mast cell density in hand-foot syndrome induced by (CR), 268
Capsaicin
 for alopecia, 537
 FDA approves Qutenza® for postherpetic neuralgia (PP), 282
Cardiac catheterization dye, fatal toxic epidermal necrolysis due to (CR), 837
Carotenoid levels in skin, correlation with previous history of skin cancer (CTR), 1289
Cathelicidin, effect of pimecrolimus cream on cathelicidin levels in eczema (CTR), 883
CC-10004. See Apremilast
CD07223 gel, efficacy and safety study in subjects with acne (CTR), 1446
CD07805/47 gel, efficacy and safety in subjects with facial erythema associated with rosacea (CTR), 1538
CDP 870. See Certolizumab pegol
Ceftaroline fosamil, FDA Advisory Committee recommends approval of (PP), 1552
Ceftobiprole, sales stopped in Canada (PP), 874
Celecoxib, inhibition of genetic BCC by (PP), 418
CEM-102, safety and efficacy vs. linezolid in bacterial skin infections (CTR), 1538
Cephalexin, using off-patent antibiotics for MRSA (CTR), 1538
Certolizumab pegol (CDP 870)
 for adult onset psoriatic arthritis (CTR), 1446
 for psoriasis and psoriatic arthritis, 947
Cetirizine, for chronic idiopathic urticaria, 503
Cetuximab, cutaneous reactions to epidermal growth factor receptor inhibitors, 1229
Charcot-Marie-Tooth disease, multiple malignant melanomas and (CR), 164
Chemotherapy
 bimatoprost ophthalmic solution in promoting eyebrow and eyelash hair growth in breast cancer patients (CTR), 82, 577
 botanicals for alopecia due to, 537
 eruption secondary to Taxotere (CR), 1534
 gemcitabine and docetaxel with or without bevacizumab in leiomyosarcoma, malignant fibrous histiocytoma and angiosarcoma (CTR), 285
 increased mast cell density in capecitabine-induced hand-foot syndrome (CR), 268
 for infantile hemangiomas (NVR), 176
 management of Merkel cell carcinoma with emphasis on small primary tumors, 105
 sorafenib-induced psoriasiform eruption in patient with metastatic thyroid carcinoma

- (CR), 169
treatment of cutaneous T-cell lymphoma with topical 5-fluorouracil (CR), 1017
urticarial hypersensitivity reaction caused by temozolomide (CR), 1142
utilizing combination or sequential treatment with 5-fluorouracil cream and destructive treatments (CR), 864
- Chilblains**, successful treatment with hydroxychloroquine, 1242
- Chitosan**, antibacterial effects of spray containing, 1237
- Chlorpromazine**, drug-associated acne and acneiform eruptions, 627
- Chronic granulomatous disease, X-linked**, voriconazole-induced photosensitivity/photodermatitis in (CR), 562
- Chronic lymphocytic leukemia**, dasatinib for unresectable or metastatic SCC or RAI stage 0–1 chronic lymphocytic leukemia (CTR), 883
- Cicatricial pemphigoid**
etanercept for (CR), 68
rituximab in (CTR), 187, 425, 577, 1289
- Ciclopirox**, antifungal activity and nail permeation of innovative ciclopirox nail lacquer, 525
- Clarisonic Opal™**, novel sonic infusion system for periorbital rhytides, 1121
- Clindamycin**
antimicrobial efficacy of benzoyl peroxide/clindamycin phosphate gel vs. clindamycin phosphate/tretinoin gel for acne vulgaris, 131
benzoyl peroxide–clindamycin combinations and skin hydration (PP), 80
comparative study of tolerability of two combination therapies for acne (CTR), 187, 425
properties of benzoyl peroxide combined with, 482
safety and efficacy of clindamycin and tretinoin gel for rosacea (CTR), 187, 285, 425, 1035, 1538
using off-patent antibiotics for MRSA (CTR), 1538
- Clinical trial review** (CTR), 82, 187, 285, 425, 577, 727, 883, 1035, 1155, 1289, 1446, 1538
- Clinical trials**
acetyl hexapeptide-8 (AH8) in treatment of blepharospasm (CTR), 82
acne relapse rate of oral minocycline vs. oral minocycline combined with topical tretinoin, followed by topical tretinoin alone (CTR), 577, 727
AIN457 regimen finding study in psoriasis (CTR), 285
ALA-PDT vs. vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 82
alemtuzumab followed by peripheral stem cell transplantation in advanced mycosis fungoides/Sézary syndrome (CTR), 883
anakinra for atopic dermatitis (CTR), 1035, 1155, 1446
antibacterial effects of a chitosan-containing spray, 1237
anti-inflammatory effects of topical dapsone for acne, 667
apremilast for lichen planus (CTR), 577, 883
apremilast for moderate-to-severe acne (CTR), 727, 1155, 1289, 1446
apremilast for rosacea (CTR), 727, 1035, 1538
apremilast in atopic or contact dermatitis (CTR), 187
arginine butyrate plus standard local therapy in patients with refractory sickle cell ulcers (CTR), 1289
assessment of mechanisms of improved wound healing (CTR), 727
atacept in generalized systemic lupus erythematosus (CTR), 1538
Atralin gel for rosacea (CTR), 1035, 1538
azelaic acid vs. hydroquinone in melasma (CTR), 727
benzoyl peroxide–clindamycin combinations and skin hydration (PP), 80
beta-blocker for chronic wound healing (CTR), 727
bevacizumab for angiosarcoma (CTR), 287
bicillin LA vs. placebo for psoriasis unresponsive to topical medications (CTR), 425
bimatoprost ophthalmic solution in promoting eyebrow and eyelash hair growth in breast cancer patients (CTR), 82, 577
BMS-833923 (XL139) in advanced or metastatic cancer (CTR), 883, 1035
botulinum toxin to treat psoriasis (CTR), 82, 1035
burn scar appearance after CO2 fractional laser treatment (CTR), 727
certolizumab pegol for adult onset psoriatic arthritis (CTR), 1446
clinical activity, safety, and tolerability of SRT2104 in subjects with psoriasis (CTR), 1446
Clinuvel Pharmaceuticals gets FDA approval for light intolerance drug trial (PP), 723
combination stem cell therapy for treatment of severe leg ischemia (CTR), 1289
combination therapy for rosacea (CTR), 187, 285, 425, 1538
comparative study of tolerability of two combination therapies for acne (CTR), 187, 425
comparison of RevLite Electro-optic Q-switched neodymium-doped yttrium aluminium garnet laser to a fractionated laser system (CTR), 82, 187, 425, 1035, 1155, 1289
comparison of safety and efficacy of ALA plus a 532 nm KTP laser vs. 532 nm KTP laser alone for facial acne, 229
comparison of SUBA™-itraconazole with SPO-RANOX® onychomycosis (CTR), 187, 285, 425
complete lymph node dissection or observation in treating patients with localized melanoma and sentinel node metastasis (CTR), 727
controlled multi-center study evaluating the efficacy of Vivité Skin Care for photoaging of face, eye and mouth, 22
correlation between skin carotenoid levels and previous history of skin cancer (CTR), 1289
dapsone gel 5% for dermatitis herpetiformis (CTR), 1155
dapsone gel in combination with adapalene gel, benzoyl peroxide gel or moisturizer for acne vulgaris, 33
dasatinib for unresectable or metastatic SCC (CTR), 285
dasatinib for unresectable or metastatic SCC or RAI stage 0–1 chronic lymphocytic leukemia (CTR), 883
dose finding and safety study of oral LEQ506 in patients with advanced solid tumors (CTR), 883
dose finding study of AEB071 assessing psoriasis area and severity index in patients with plaque psoriasis (CTR), 285
effect of lidocaine when mixed with large gel particle hyaluronic acid filler on tolerability and longevity, 1097
effect of pimecrolimus cream on cathelicidin levels in eczema (CTR), 883
effect of thymosin beta-4 on wound healing in epidermolysis bullosa (CTR), 727
effects of fractional carbon dioxide laser treatment prior to wound closure (CTR), 1155
effects of pulsed-dye laser on scar formation (CTR), 727, 1155
effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 1289
efficacy and safety of adding methotrexate to etanercept in psoriasis (CTR), 82
efficacy and safety of ASP015K in psoriasis (CTR), 1035, 1446
efficacy and safety of CD07223 gel in subjects with acne (CTR), 1446
efficacy and safety of CD07805/47 gel in subjects with facial erythema associated with rosacea (CTR), 1538
efficacy and safety of GDC-0449 in patients with advanced BCC (CTR), 82, 285
efficacy and safety of iontophoretic application of terbinafine gel in onychomycosis (CTR), 577, 1155
efficacy and safety of omalizumab in bullous pemphigoid (CTR), 187, 425, 577, 1289
efficacy and safety of Visonac PDT for acne (CTR), 1155, 1289, 1446
efficacy and safety study of 3.75% imiquimod cream following cryosurgery for AK, 1101
efficacy and tolerance of novel phenolic antioxidant skin care system, 1480
efficacy of 15% azelaic acid in psoriasis, 964
efficacy of hexapeptide-7 on menopausal skin, 49
efficacy of itraconazole in BCC (CTR), 883, 1035
efficacy of spray silicone in alteration of burn scar (CTR), 727
efficacy of triamcinolone 0.1% cream occluded with hydrogel patch vs. triamcinolone 0.1% cream without occlusion for eczema (CTR), 883
efficacy of Ultravate ointment in combination with Lac-Hydrin cream for psoriasis (CTR), 285, 577, 1035
electronic brachytherapy for non-melanoma skin cancer (CTR), 1035
Emervel Classic Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
Emervel Deep Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
EPB-348 for herpes zoster (CTR), 1035
Epiduo® pediatric acne study (CTR), 1155
erlotinib and radiotherapy for cutaneous SCC (CTR), 82, 285
erlotinib for psoriasis (CTR), 82, 187, 285, 425, 577, 1035, 1446
erlotinib in women with SCC of vulva (CTR), 1289
erlotinib prior to surgery or radiation in patients with SCC (CTR), 883, 1289
Ertaczo® relieves itching (PP), 80
etanercept for chronic urticaria (CTR), 1155
etanercept in lichen planus (CTR), 187, 425, 577
evaluation of single dose of ILV-095 in psoriasis subjects (CTR), 285, 577, 1035, 1446
exSALT SD7™ compared to Xeroform® petrolatum dressing for management of partial thickness donor sites (CTR), 727
face and neck revitalization with platelet-rich plasma, 466
fluphenazine hydrochloride for psoriasis (CTR), 187, 425, 1446
FV-100 vs. valacyclovir for herpes zoster (CTR), 1035
gemcitabine and docetaxel with or without bevacizumab in leiomyosarcoma, malignant fibrous histiocytoma and angiosarcoma (CTR), 290
GSK2132231A antigen-specific immunotherapeutic in patients with inoperable metastatic cutaneous melanoma (CTR), 727, 1289
Hairmax Lasercomb for androgenetic alopecia in females (CTR), 1446

- Helix BioPharma and topical interferon alpha-2b for anogenital warts (PP), 723
- hematopoietic stem cell support in patients with autoimmune bullous skin disorders (CTR), 1289
- human monoclonal antibody zanolimumab to treat mycosis fungoides/Sézary syndrome (CTR), 883
- hydroxychloroquine efficacy in chronic urticaria (CTR), 1155
- imatinib in scleroderma (PP), 80
- injectable biologic and U0279 combination therapy for psoriasis (CTR), 285
- ipilimumab in young patients with advanced or refractory solid tumors (CTR), 883
- IVIG with or without cyclophosphamide in pemphigus (CTR), 1289
- laser treatment for fresh surgical scars and mature scars (CTR), 727, 1155
- lenalidomide for mycosis fungoides/Sézary syndrome (CTR), 883
- light therapy for toenail fungus (CTR), 285, 577, 1155
- long-term efficacy and safety of topical PRK 124 lotion for rosacea, 647
- long-term safety and efficacy of etanercept in psoriasis, 928
- MAGE-A3 antigen-specific cancer immunotherapeutic in patients with progressive metastatic cutaneous melanoma (CTR), 1289
- management of pruritus with Xyzal in atopic dermatitis (CTR), 82
- minoxidil for female pattern hair loss (CTR), 1446
- multi-wavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented skin lesions (CTR), 1035
- MyoScience Tissue Remodeling Device for facial rejuvenation (CTR), 577
- Nd:YAG laser for acne keloidalis nuchae (CTR), 577
- nilotinib in TKI resistant or intolerant patients with metastatic mucosal, acral, or chronically sundamaged melanoma (CTR), 883
- novel treatment for syndromic ichthyoses (CTR), 1155
- oral glutamine to suppress recurrent herpes labialis (CTR), 285
- PDT to treat actinic damage in patients with SCC of lip (CTR), 82, 1289
- PDT using ALA in treating patients with skin cancer (CTR), 82
- PDT with MAL cream in patients with skin type V or IV with acne (CTR), 187, 425
- pediatric longitudinal evaluation of long-term safety of Protopic® for atopic dermatitis (CTR), 1446
- PEG-interferon alfa-2b and UV light therapy in mycosis fungoides/Sézary syndrome (CTR), 883
- pegylated interferon for children with high-risk melanoma (CTR), 727, 1289
- pharmacokinetics and safety of luliconazole solution in distal subungual onychomycosis (CTR), 577, 1155
- phase 1 study of ND0611 dermal patch (PP), 1033
- pimecrolimus cream for cutaneous lesions of pemphigus vulgaris, 684
- positive phase 2b clinical trial of psoriasis drug apremilast (PP), 282
- randomized clinical studies of adapalene lotion for acne, 639
- Restylane and Perlane in correction of peri-oral wrinkles (CTR), 187
- retapamulin vs. linezolid in treatment of SITL or impetigo due to MRSA (CTR), 82, 1538
- rituximab in ocular cicatricial pemphigoid (CTR), 187, 425, 577, 1289
- safety and effectiveness of etanercept for lichen planus of oral mucosa or skin (CTR), 577, 883
- safety and efficacy of abatacept in subjects with chronic urticaria after inadequate response to antihistamine therapy (CTR), 82, 1155
- safety and efficacy of BFH772 in psoriasis patients (CTR), 189, 425
- safety and efficacy of CEM-102 vs. linezolid in bacterial skin infections (CTR), 1538
- safety and efficacy of clindamycin and tretinoin gel for rosacea (CTR), 187, 285, 425, 1035, 1538
- safety and efficacy of etanercept for discoid lupus erythematosus (CTR), 1538
- safety and efficacy of EXC 001 to improve appearance of scars from prior breast surgery (CTR), 728
- safety and efficacy of IDP-107 in patients with acne vulgaris (CTR), 1446
- safety and efficacy of NAB001 for onychomycosis of toenails (CTR), 1538
- safety and efficacy of oral nalfurafine HCl (AC-820) in subjects on hemodialysis with uremic pruritus (CTR), 82
- safety and efficacy of tazarotene cream and adapalene gel in facial acne vulgaris, 549
- safety and efficacy of tazarotene foam 0.1% in subjects with facial acne (CTR), 187, 425, 1446
- safety and efficacy of topical IDP-108 vs. vehicle in onychomycosis (CTR), 285, 577, 1538
- safety and efficacy of ustekinumab in psoriatic arthritis patients who have prior exposure to anti-TNF agents (CTR), 1155
- safety and pharmacokinetics of famciclovir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 285
- safety and pharmacokinetics of new formulation of bimatoprost in alopecia (CTR), 1446
- safety, local tolerability, pharmacokinetics, and pharmacodynamics of LDE225 on sporadic superficial skin BCC (CTR), 285, 883, 1035
- safety of adult stem cells to treat patients with severe leg artery disease (CTR), 1289
- safety of teplizumab (MGA031) in subjects with moderate or more severe psoriasis (CTR), 82, 187, 425, 577
- safety of topical doxycycline gel for adult diabetic lower extremity ulcers (CTR), 82
- safety study of AMG 157 in healthy subjects and subjects with atopic dermatitis (CTR), 883, 1035, 1155, 1446
- Soligenix study of orBec® for prevention of GVHD (PP), 1033
- spironolactone pills vs. minoxidil lotion in female pattern hair loss (CTR), 577
- study of effects of increasing doses of drug for nail fungus (CTR), 189, 427
- TDT 067 onychomycosis study (CTR), 1538
- terminology for vehicle vs. placebo in, 1221
- tolerability and efficacy of novel formulation in treatment of melasma, 215
- tolerability and efficacy of two topical therapies for keloids and hypertrophic scars, 514
- topical cidofovir for prevention of hair growth (CTR), 82
- topical cyclosporin for ocular rosacea (CTR), 285
- topical perillyl alcohol in treating patients with sun damaged skin and AK (CTR), 82
- topical vitamin B12 for childhood atopic dermatitis (CTR), 1155, 1446
- topically dissolved oxygen (TDO) to ameliorate signs of photodamage (CTR), 187, 425
- TR-701 for bacterial skin infections (CTR), 1538
- treating onychomycosis (CTR), 187, 425, 1538
- treating photodamage of décolletage area with novel copper zinc malonate complex plus hydroquinone and tretinoin, 220
- treatment of alopecia areata of scalp with intradermal injections of botulinum toxin (CTR), 82
- treatment of androgenetic alopecia in females, 12 beam (CTR), 1446
- treatment of atopic dermatitis with concurrent Altabax® and topical low-potency corticosteroids vs. low-potency corticosteroid monotherapy (CTR), 883, 1035
- treatment of forehead/glabellar rhytide complex with combination botulinum toxin A and hyaluronic acid vs. botulinum toxin injection alone (CTR), 1538
- treatment of surgical scars with pulsed dye laser (CTR), 727
- trial of Dermacorder for detecting malignant skin lesions (CTR), 883
- Trius Therapeutics phase 3 study of torezolid phosphate (PP), 1160
- using off-patent antibiotics for MRSA (CTR), 1538
- UV light exposure and immunosuppression in cutaneous melanoma (CTR), 1289
- vaccine therapy in stage IV cutaneous melanoma (CTR), 1292
- VB-201 for psoriasis (CTR), 1037, 1449
- ZD1839 for recurrent or metastatic SCC of skin (CTR), 885
- Clobetasol propionate**, therapeutic shampoos for targeting symptoms of inflammatory scalp disorders, 41
- CNTO-148**. See Golimumab
- CNTO-1275**. See Ustekinumab
- Coal tar preparations**, evidence-based review in treatment of psoriasis and atopic dermatitis, 1258
- Coffea arabica extract*
- efficacy and tolerance of novel phenolic antioxidant skin care system containing, 1480
- oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11
- Colchicine**, in treatment of morphea, 1213
- Collagen**
- fillers for facial shaping, s129 (August)
- histopathologic identification of dermal filler agents, 1072
- Collagen-glycosaminoglycan copolymer**, for severe chest keloids, 542
- Colloidal oatmeal**, 1116
- Combat dermatology**, prevalence of skin disease in deployed dermatology clinic in Iraq, 210
- Complement**
- potential role in immune evasion by *Mycobacterium leprae*, 1373
- role in dendritic cell control of T-cell subsets (editorial), 1364
- Contact dermatitis**
- apremilast in atopic dermatitis or (CTR), 187
- thalidomide and analogues for, 814
- CoolSculpting**, Zeltiq receives FDA clearance (PP), 1552
- Copper zinc malonate complex**, plus hydroquinone and tretinoin for treating photodamage of décolletage area, 220
- Corticosteroids**
- adherence and efficacy of desonide hydrogel for atopic dermatitis, 324
- drug-associated acne and acneiform eruptions, 627
- FDA approval of mometasone furoate topical solution USP, 0.1% (PP), 1455

- hydrocortisone, silicone and vitamin E lotion for keloids and hypertrophic scars, 514
for infantile hemangiomas (NVR), 176
for infantile hemangiomas, immune function impaired by (PP), 1033
pediatric indication for Locoid Lipocream® cream (PP), 80
safety and HPA axis effects of two-compound ointment containing calcipotriene/betamethasone dipropionate for psoriasis, 969
therapeutic shampoos for targeting symptoms of inflammatory scalp disorders, 41
treatment of atopic dermatitis with concurrent Altabax® and topical low-potency corticosteroids vs. low-potency corticosteroid monotherapy (CTR), 883, 1035
versus. tacrolimus for pruritus in atopic dermatitis, 488
in treatment of morphea, 1213
- Cosmetic dermatology**
attaining predictable aesthetic results with dermal fillers, 458
Belotero dermal filler close to FDA approval (PP), 1455
calcium hydroxyapatite in nonsurgical aesthetic rejuvenation, 446
controlled multi-center study evaluating the efficacy of Vivité Skin Care for photoaging of face, eye and mouth, 22
correction of atrophic acne scars with Artefill®, 1062
cosmeceuticals in clinical practice, s62 (May)
current and future botulinum neurotoxin type A preparations in aesthetics, 1065
dermal effects of nanoparticles, 475
effect of lidocaine when mixed with large gel particle hyaluronic acid filler on tolerability and longevity, 1097
efficacy and tolerance of novel phenolic antioxidant skin care system, 1480
Emervel Classic Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
Emervel Deep Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
expanding the use of neurotoxins in facial aesthetics, s7 (January)
face and neck revitalization with platelet-rich plasma, 466
failure of botulinum toxin treatment for localized vitiligo, 1092
FDA approves Juvéderm® XC with lidocaine (PP), 418
first fractional laser FDA cleared for stretch marks (PP), 418
formulation composition of botulinum toxins in clinical use, 1085
histopathologic identification of dermal filler agents, 1072
hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for aesthetic rejuvenation therapy (BC), 1135
injection techniques for revolumization of perioral region with hyaluronic acid, 367
lip tenting technique, 559
localization and histology of injected hyaluronic acid in excised nasolabial fold tissue (CR), 399
Mederma® for stretch marks (PP), 418
minimally invasive techniques for periorbital rejuvenation, s118 (August)
novel sonic infusion system for periorbital rhytides, 1121
pain with Radiesse® with lidocaine for nasolabial folds (CTR), 577
practical applications of a new botulinum toxin, s31 (March)
prospective study of improvement in periorbital wrinkles and eyebrow elevation with novel fractional CO2 laser—the fractional eyelift, 16
PureGraft™ System receives marketing clearance (PP), 723
retrospective review of 500 patients treated with abobotulinumtoxinA, 1081
SkinMedica launches new Rejuvenize Peel™ (PP), 418
SmartLipoTriplex™ for liposuction (PP), 80
Solta Medical to buy Aesthera Corp. (PP), 418
treatment of facial atrophic scars with Esthélics, 1507
use of injectable poly-L-lactic acid in people of color, 451
Zerona now FDA-approved for body slimming (PP), 1455
- Cost effectiveness**, of botulinum toxins for treatment of depression, 27
- Coumadin necrosis**, drug therapy for, 341
- Cow udder ointment**, drug-associated acne and acneiform eruptions, 627
- Cryopneumatic technology**, stratum corneum permeation and percutaneous drug delivery of hydrophilic molecules enhanced by, 1528
- Cryosurgery**
for actinic keratoses, s45 (May)
efficacy and safety study of 3.75% imiquimod cream following cryosurgery for AK, 1101
medical and surgical management of keloids, 1249
utilizing combination or sequential treatment with 5-fluorouracil cream and destructive treatments (CR), 864
- CTLA4 therapy**, autoimmune complications of (CR), 1432
- Cutaneous aging**. See also Photoaging
controlled multi-center study evaluating the efficacy of Vivité Skin Care for photoaging of face, eye and mouth, 22
efficacy of hexapeptide-7 on menopausal skin, 49
oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11
- Cutaneous angioimmunoblastic T-cell lymphoma** (CR), 851
- Cutaneous lupus erythematosus**
anti-TNF- α therapy and (CR), 1283
development associated with use of imiquimod to treat AK (CR), 1022
in pregnancy (NVR), 1297
thalidomide and analogues for, 814
- Cutaneous necrosis, acute**, drug therapy for, 341
- Cutaneous pseudolymphoma**, ALA-PDT for (CR), 688
- Cutaneous T-cell lymphoma**
alemtuzumab followed by peripheral stem cell transplantation in advanced mycosis fungoides/Sézary syndrome (CTR), 883
angioimmunoblastic (CR), 851
development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome (CR), 1014
human monoclonal antibody zanolimumab to treat mycosis fungoides/Sézary syndrome (CTR), 883
Istodax for (PP), 183
lenalidomide for mycosis fungoides/Sézary syndrome (CTR), 883
PEG-interferon alfa-2b and UV light therapy in mycosis fungoides/Sézary syndrome (CTR), 888
role of phototherapy in, 764
maintenance phototherapy, 800
- successful treatment with topical 5-fluorouracil (CR), 1017
thalidomide and analogues for, 814
- Cyclophosphamide**, IVIG with or without, in pemphigus (CTR), 1289
- Cyclosporine**
drug-associated acne and acneiform eruptions, 627
non-Hodgkin's B-cell lymphoma in a psoriatic patient (CR), 1277
ophthalmic solution, for ocular rosacea (CTR), 285
- Cytokines**, effect of thalidomide on nitric oxide production in RAW 264.7 cells, 330

D

- Dabo**, for alopecia, 537
- Dactinomycin**, drug-associated acne and acneiform eruptions, 627
- Danazol**, drug-associated acne and acneiform eruptions, 627
- Dantrolene**, drug-associated acne and acneiform eruptions, 627
- Dapsone**
anti-inflammatory effects of topical dapsone for acne, 667
dapsone gel 5% for dermatitis herpetiformis (CTR), 1155
dapsone gel in combination with adapalene gel, benzoyl peroxide gel or moisturizer for acne vulgaris, 33
drug-associated acne and acneiform eruptions, 627
safety in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients, 532
- Dasatinib**
for unresectable or metastatic SCC (CTR), 285
for unresectable or metastatic SCC or RAI stage 0–1 chronic lymphocytic leukemia (CTR), 883
- Decubitus ulcers**, oxandrolone treatment of (CR), 711
- Delusions of parasitosis**, aripiprazole for (CR), 1531
- Dendritic cells in immunotherapy**
potential role for complement in immune evasion by Mycobacterium leprae, 1373
role of complement in dendritic cell control of T-cell subsets (editorial), 1364
T cells and, 1383
TH17 in regression of metastatic melanoma to topical diphenylprone, 1368
- Depression**, cost effectiveness of botulinum toxins for treatment of, 27
- Dermacorder**, for detecting malignant skin lesions (CTR), 883
- Dermatitis herpetiformis**, dapsone gel 5% for (CTR), 1155
- Dermatologists**
approaching psoriasis: patient-physician relationships, patient education and choosing the right topical vehicle, 908
identifying the right dermatologic surgery fellowship for you (RR), 421
- Dermatomyositis**, Wong type, 1475
- Dermoscopy**, impact on skin cancer diagnostics, 129
- Desloratadine**, for chronic idiopathic urticaria, 503
- Desonide hydrogel**, adherence and efficacy for atopic dermatitis, 324
- Devices and equipment**
AccuView DV-5 Multi Imaging System (PP), 418
comparison of RevLite Electro-optic Q-switched neodymium-doped yttrium aluminium garnet laser to a fractionated laser system (CTR), 82,

187, 425, 1035, 1155, 1289
 FDA 510(k) clearance of Fraxel re:store Dual Laser for AK (PP), 1552
 FDA approval of eMatrix device (PP), 572
 FDA approves Exilis body shaping as nonsurgical device (PP), 874
 FDA approves Ulthera's ultrasound product (PP), 282
 FDA panel makes tanning bed recommendations (PP), 874
 flexible scalpel for minimally invasive and minimally scarring surgery for large scalp tumors, 1268
 Groove Optic™ for Lux2940™ for fractional skin resurfacing (PP), 183
 Hairmax Lasercomb for androgenetic alopecia in females (CTR), 1446
 modified scalpel in hair restoration, 1266
 MyoScience Tissue Remodeling Device for facial rejuvenation (CTR), 577
 novel sonic infusion system for periorbital rhytides, 1121
 PureGraft™ System receives marketing clearance (PP), 723
 single-spot, 2940-nm Er:YAG dual-mode laser treatment of facial acne scars, 1341
 tattoo treatment with alexandrite laser with two Nd:YAG laser handpieces pumped by alexandrite treatment beam, 1333
 TempASSURE device (PP), 418
 trial of Dermacorder for detecting malignant skin lesions (CTR), 883
 VECTRA M3 facial imaging system (PP), 418
 Zeltiq receives FDA clearance (PP), 1552
 Zerona now FDA-approved for body slimming (PP), 1455

Diabetes mellitus
 iron overload and diabetic wounds (NVR), 719
 prompt biological therapy speeds diabetic foot ulcer healing (PP), 1455
 safety of topical doxycycline gel for adult diabetic lower extremity ulcers (CTR), 82

Diet/nutrition, Heliocare® (PP), 183

Diphencyprone, topical, TH17 in regression of metastatic melanoma to, 1368

DNA repair enzyme creams, reduced number of AK with, 1519

Docetaxel
 eruption secondary to (CR), 1534
 and gemcitabine with or without bevacizumab in leiomyosarcoma, malignant fibrous histiocytoma and angiosarcoma (CTR), 285

Doxycycline
 efficacy and safety of doxycycline and minocycline for acne, 1407
 efficacy of topical azelaic acid gel plus oral doxycycline vs. metronidazole gel plus oral doxycycline in rosacea, 607
 safety of topical gel for adult diabetic lower extremity ulcers (CTR), 82

Drug delivery
 hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for aesthetic rejuvenation therapy, 1135
 safety and efficacy of topical 4% lidocaine gel in unique drug delivery system, 1500
 stratum corneum permeation and percutaneous drug delivery of hydrophilic molecules enhanced by cryopneumatic and photopneumatic technologies, 1528

Drug reactions/toxicity
 annular leukocytoclastic vasculitis associated with sorafenib (CR), 697
 atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57
 bupropion-induced Stevens-Johnson syndrome with acute psoriatic exacerbation (CR), 1010
 cutaneous fixed drug eruption to fluconazole (CR), 1025
 cutaneous lupus erythematosus and anti-TNF- α therapy (CR), 1283
 cutaneous nontuberculous mycobacterial abscesses associated with insulin injections (CR), 1439
 cutaneous reactions to epidermal growth factor receptor inhibitors, 1229
 dermatologic emergencies (NVR), 1545
 development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome (CR), 1014
 development of subacute cutaneous lupus erythematosus associated with use of imiquimod to treat AK (CR), 1022
 drug-associated acne and acneiform eruptions, 627
 eruption secondary to Taxotere (CR), 1534
 fatal toxic epidermal necrolysis due to cardiac catheterization dye (CR), 837
 fluconazole-associated Stevens-Johnson syndrome (CR), 1272
 increased mast cell density in capecitabine-induced hand-foot syndrome (CR), 268
 isotretinoin and inflammatory bowel disease and (NVR), 278
 levetiracetam-induced reticulated drug eruption (CR), 409
 non-Hodgkin's B-cell lymphoma in a psoriatic patient (CR), 1277
 oral lichenoid drug reaction associated with anti-hypertensive and hypoglycemic drugs (CR), 73
 postpubertal eruptive syringoma triggered with antiepileptic drugs (CR), 707
 progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab (CR), 1005
 red man syndrome (NVR) and, 76
 sorafenib-induced psoriasiform eruption in patient with metastatic thyroid carcinoma (CR), 169
 Tamiflu®, and 76
 tigecycline linked to increased mortality risk (PP), 1455
 urticarial hypersensitivity reaction caused by temozolomide (CR), 1142
 voriconazole-induced photosensitivity/photoaging in X-linked chronic granulomatous disease (CR), 562
 warfarin-induced skin necrosis mimicking calciphylaxis (CR), 859

Drug resistance
 avoiding antimicrobial resistance in treatment of acne, 519
 development of antimicrobial resistance due to antibiotic treatment of acne, 655
 methicillin-resistant *S. aureus* infection, new antibiotics for, and (NVR), 76
 oregano-based ointment with antimicrobial activity against, 377
 retapamulin vs. linezolid in treatment of SITL and impetigo due to (CTR), 82, 1545
 Sanofi Pasteur and Syntiron development of MRSA vaccine (PP), 282
 using off-patent antibiotics for (CTR), 1538
 retapamulin in age of *S. aureus* antimicrobial resistance, 1198

E

Eating disorders, dermatologic indicators of (NVR), 412

Ecallantide, FDA approval for hereditary angioedema (PP), 572

Economic issues
 cost effectiveness of botulinum toxins for treatment of depression, 27
 cost-effectiveness of tacrolimus ointment vs. pimecrolimus cream for atopic dermatitis, 372
 Solta Medical to buy Aesthera Corp. (PP), 418

Ecthyma gangrenosum, drug therapy for, 341

Eczema. See Atopic dermatitis

Editorials
 Miami heat (editorial), 208
 role of complement in dendritic cell control of T-cell subsets, 1364
 we are making progress with acne and rosacea, 603

Efalizumab
 how and when to use biologics in psoriasis, s106 (August)
 progressive multifocal leukoencephalopathy in two psoriasis patients treated with (CR), 1005
 for resistant plaque psoriasis (PP), 183
 use in pediatric psoriasis, 975

Emergencies, dermatologic (NVR), 1545

EPB-348, for herpes zoster (CTR), 1035

Epidermal growth factor receptor inhibitors
 cutaneous reactions to, 1229
 drug-associated acne and acneiform eruptions, 627

Epidermolysis bullosa, effect of thymosin beta-4 on wound healing in (CTR), 727

Epigallocatechin gallate (EGCG)
 for cancer-related alopecia, 537
 cosmeceuticals in clinical practice, s62 (May)

Erbix®. See Cetuximab

Erlotinib
 cutaneous reactions to epidermal growth factor receptor inhibitors, 1229
 drug-associated acne and acneiform eruptions, 627
 prior to surgery or radiation in patients with SCC (CTR), 883, 1289
 for psoriasis (CTR), 82, 187, 285, 425, 577, 1035, 1446
 and radiotherapy for cutaneous SCC (CTR), 82, 285

Ertaczo®. See Sertaconazole nitrate cream

Eruptive syringoma, postpubertal, triggered with antiepileptic drugs (CR), 707

Erythema nodosum leprosum, thalidomide and analogues for, 814

Erythromelalgia, gabapentin for (CR), 565

Estrogen, efficacy of hexapeptide-7 on menopausal skin, 49

Etanercept
 for chronic urticaria (CTR), 1155
 efficacy and safety of adding methotrexate to, in psoriasis (CTR), 82
 for familial pityriasis rubra pilaris (CR), 844
 how and when to use biologics in psoriasis, s106 (August)
 in lichen planus (CTR), 187, 425, 577
 long-term safety and efficacy in psoriasis, 928
 for recalcitrant cicatricial pemphigoid (CR), 68
 safety and effectiveness for lichen planus of oral mucosa or skin (CTR), 577, 883
 safety and efficacy in discoid lupus erythematosus (CTR), 1538
 and U0279 combination therapy for psoriasis (CTR), 285
 use in pediatric psoriasis, 975

- versus ustekinumab for psoriasis (PP), 572
- Etretinate**, drug-associated acne and acneiform eruptions, 627
- EXC 001**, safety and efficacy to improve appearance of scars from prior breast surgery (CTR), 728
- Exfoliative erythroderma** (NVR), 1545
- exSALT SD7™**, compared to Xeroform® petrolatum dressing for management of partial thickness donor sites (CTR), 727
- Eye drops**, effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 1289
- Eyebrow**
bimatoprost ophthalmic solution in promoting eyebrow and eyelash hair growth in breast cancer patients (CTR), 82, 577
prospective study of improvement in periorbital wrinkles and eyebrow elevation with novel fractional CO2 laser—the fractional eyelift, 16
- Eyelashes**, bimatoprost ophthalmic solution in promoting eyebrow and eyelash hair growth in breast cancer patients (CTR), 82, 577
- Eyelid**, acetyl hexapeptide-8 (AH8) in treatment of blepharospasm (CTR), 82
- Ezetimibe**, hair growth in patients with alopecia areata totalis after treatment with simvastatin and (CR), 62
- F**
- Facial lipatrophy**, monophasic, cohesive-polydensified-matrix crosslinking-technology-based HA filler for facial lipatrophy in HIV-infected patients (CR), 690
- Facial rejuvenation**
calcium hydroxyapatite in nonsurgical aesthetic rejuvenation, 446
Emervel Classic Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
Emervel Deep Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
face and neck revitalization with platelet-rich plasma, 466
fillers for facial shaping, s129 (August)
hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for aesthetic rejuvenation therapy, 1135
minimally invasive techniques for periorbital rejuvenation, s118 (August)
MyoScience Tissue Remodeling Device for (CTR), 577
SkinMedical launches new Rejuvenize Peel™ (PP), 418
- Famciclovir**, safety and pharmacokinetics of famciclovir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 285
- Familial pityriasis rubra pilaris** (CR), 844
- Fat**
autologous, for facial shaping, s129 (August)
dual-wavelength laser lipolysis treatment of lipomas (CR), 387
fat necrosis/panniculitis and polyarthritis associated with pancreatic acinar cell carcinoma (CR), 1145
fat transplant in treatment of morphea, 1213
FDA issues warning letters about claims regarding lipodissolve (PP), 874
laser lipolysis with 980 nm diode laser, s58 (May)
monophasic, cohesive-polydensified-matrix crosslinking-technology-based HA filler for facial lipatrophy in HIV-infected patients (CR), 690
PureGraft™ System receives marketing clearance (PP), 723
SmartLipo Triplex™ for liposuction (PP), 80
- Zeltiq receives FDA clearance (PP), 1552
- Fellowships**, identifying the right dermatologic surgery fellowship for you (RR), 421
- Fexofenadine**, for chronic idiopathic urticaria, 503
- Field cancerization**, for actinic keratoses, s45 (May)
- Fluconazole**
cutaneous fixed drug eruption to (CR), 1025
Stevens-Johnson syndrome associated with (CR), 1272
- Fluocinolone acetonide**, therapeutic shampoos for targeting symptoms of inflammatory scalp disorders, 41
- 5-Fluorouracil**
medical and surgical management of keloids, 1249
topical
successful treatment of cutaneous T-cell lymphoma with topical (CR), 1017
utilizing combination or sequential treatment with 5-fluorouracil cream and destructive treatments (CR), 864
- Fluphenazine hydrochloride**, for psoriasis (CTR), 187, 425, 1446
- Foot lesions**
efficacy and safety of new topical keratolytic treatment for palmoplantar keratoderma, 1512
gabapentin for erythromelalgia (CR), 565
increased mast cell density in capecitabine-induced hand-foot syndrome (CR), 268
prompt biological therapy speeds diabetic foot ulcer healing (PP), 1455
safety of topical doxycycline gel for adult diabetic lower extremity ulcers (CTR), 82
- Fractional eyelift**, prospective study of improvement in periorbital wrinkles and eyebrow elevation with novel fractional CO2 laser, 16
- Fractionated laser therapy**
appearance of burn scar after CO2 fractional laser treatment (CTR), 727
comparison of RevLite Electro-optic Q-switched neodymium-doped yttrium aluminium garnet laser to a fractionated laser system (CTR), 84, 187, 425, 1035, 1155, 1289
effects of fractional carbon dioxide laser treatment prior to wound closure (CTR), 1155
first fractional laser FDA cleared for stretch marks (PP), 418
fractional photothermolysis for depressed alar scar following Mohs micrographic surgery (CR), 66
Groove Optic™ for Lux2940™ for fractional skin resurfacing (PP), 183
of mature thermal burn scars (CR), 389
prospective study of improvement in periorbital wrinkles and eyebrow elevation with novel fractional CO2 laser—the fractional eyelift, 16
treatment of CO2 laser induced hypopigmentation with ablative fractionated laser resurfacing (CR), 1420
ultrapulsed fractional CO2 laser for post-traumatic and pathological scars, 1328
- Fungal infection**
antifungal activity and nail permeation of innovative ciclopirox nail lacquer, 525
comparison of SUBA™-itraconazole with SPO-RANOX® for onychomycosis (CTR), 187, 285, 425
efficacy and safety of iontophoretic application of terbinafine gel in onychomycosis (CTR), 577, 1155
light therapy for toenail fungus (CTR), 285, 577, 1155
onychomycosis therapy, 1109
- pharmacokinetics and safety of luliconazole solution in distal subungual onychomycosis (CTR), 577, 1155
safety and efficacy of NAB001 for onychomycosis of toenails (CTR), 1538
safety and efficacy of topical IDP-108 vs. vehicle in onychomycosis (CTR), 285, 577, 1538
study of effects of increasing doses of drug for nail fungus (CTR), 187, 425
TDT 067 onychomycosis study (CTR), 1538
treating onychomycosis (CTR), 187, 425
FV-100, vs. valacyclovir for herpes zoster (CTR), 1035
- G**
- Gabapentin**, for erythromelalgia (CR), 565
- Garlic**, for alopecia, 537
- GDC-0449**, efficacy and safety in patients with advanced BCC (CTR), 82, 285
- Gefitinib**
cutaneous reactions to epidermal growth factor receptor inhibitors, 1229
drug-associated acne and acneiform eruptions, 627
for recurrent or metastatic SCC of skin (CTR), 883
- Gemcitabine**, and docetaxel with or without bevacizumab in leiomyosarcoma, malignant fibrous histiocytoma and angiosarcoma (CTR), 285
- Genetics**
celecoxib inhibition of genetic BCC (PP), 418
pathogenesis, genetics and medical treatment of patterned hair loss, 1412
steroid sulfatase gene deletion in Egyptian males with X-linked ichthyosis, 1192
voriconazole-induced photosensitivity/photoaging in X-linked chronic granulomatous disease (CR), 562
- Genital warts**, FDA approves new indications for HPV vaccine (PP), 80
- Glaucoma drugs**, effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 1289
- Glucose-6-phosphate dehydrogenase deficiency**, safety of dapsone in, 532
- Glutamine**, to suppress recurrent herpes labialis (CTR), 285
- Glycolic acid**, tolerability and efficacy of novel formulation in treatment of melasma, 215
- Gold**, drug-associated acne and acneiform eruptions, 627
- Golimumab**, for psoriasis and psoriatic arthritis, 947
- Graft-versus-host disease (GVHD)**, Soligenix study of orBec® for prevention of (PP), 1033
- Granulocyte colony-stimulating factor**, drug-associated acne and acneiform eruptions, 627
- Green tea**
for cancer-related alopecia, 537
cosmeceuticals in clinical practice, s62 (May)
- GSK2132231A antigen-specific immunotherapeutic**, in patients with inoperable metastatic cutaneous melanoma (CTR), 727, 1289
- H**
- Hair**
modified scalpel in hair restoration (BC), 1266
topical cidofovir for prevention of hair growth (CTR), 82
- Hair loss**
bimatoprost ophthalmic solution in promoting eyebrow and eyelash hair growth in breast cancer patients (CTR), 82, 577
botanical approaches to alopecia, 537

- hair growth in patients with alopecia areata totalis after treatment with simvastatin and ezetimibe (CR), 62
- Hairmax Lasercomb for androgenetic alopecia in females (CTR), 1446
- minoxidil for female pattern hair loss (CTR), 1446
- new study implicates autoimmune mechanisms in alopecia areata (PP), 1160
- pathogenesis, genetics and medical treatment of patterned hair loss, 1412
- safety and pharmacokinetics of new formulation of bimatoprost in alopecia (CTR), 1446
- spironolactone pills vs. minoxidil lotion in female pattern hair loss (CTR), 577
- treatment of alopecia areata of scalp with intradermal injections of botulinum toxin (CTR), 82
- treatment of androgenetic alopecia in females, 12 beam (CTR), 1446
- Hairmax Lasercomb** for androgenetic alopecia in females (CTR), 1446
- treatment of androgenetic alopecia in females, 12 beam (CTR), 1446
- Halobetasol propionate ointment**, efficacy of Ultravate ointment in combination with Lac-Hydrin cream for psoriasis (CTR), 285, 577, 1035
- Halogens**, drug-associated acne and acneiform eruptions, 627
- Hand lesions**
- efficacy and safety of new topical keratolytic treatment for palmoplantar keratoderma, 1512
- increased mast cell density in capecitabine-induced hand-foot syndrome (CR), 268
- rapid improvement in digital ischemia and acral contracture in collodion baby treated with topical tazarotene (CR), 713
- unilateral lichen planus pigmentosus mimicking acral lentiginous melanoma (CR), 841
- Hand sanitizers**, FDA warns consumers in Puerto Rico of harmful bacteria in (PP), 874
- Head lice**, benzyl alcohol lotion 5% for (PP), 572
- Hedgehog pathway inhibitor**, efficacy and safety of GDC-0449 in patients with advanced BCC (CTR), 82, 285
- Heliocare**® (PP), 187
- Hemangiomas, infantile**
- corticosteroid treatment impairs immune function (PP), 1033
- current treatments for (NVR), 176
- pulsed dual-wavelength 595 and 1064 nm in management of, 310
- Hemodialysis patients**, safety and efficacy of oral nalfurafine HCl (AC-820) for uremic pruritus in (CTR), 82
- Hemostasis**, comparative efficacy and safety of topical hemostatic powder and sterile compressed foam sponge in second intention healing after Mohs micrographic surgery, 137
- Heparin necrosis**, drug therapy for, 341
- Herbal remedies**
- for alopecia, 537
- oregano-based ointment with antimicrobial activity against MRSA, 377
- Hereditary angioedema**, FDA approval of ecalantide for (PP), 572
- Hereditary hemochromatosis** (NVR), 719
- Herpes gestationis** (NVR), 1297
- Herpetic disease**
- EPB-348 for herpes zoster (CTR), 1035
- FDA approves Qutenza® for postherpetic neuralgia (PP), 282
- FV-100 vs. valacyclovir for herpes zoster (CTR), 1035
- oral glutamine to suppress recurrent herpes labialis (CTR), 285
- safety and pharmacokinetics of famciclovir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 285
- Hexapeptide-7**, efficacy on menopausal skin, 49
- Histology**
- annular leukocytoclastic vasculitis associated with sorafenib (CR), 697
- cutaneous fixed drug eruption to fluconazole (CR), 1025
- cutaneous lupus erythematosus and anti-TNF- α therapy (CR), 1283
- eruption secondary to Taxotere (CR), 1534
- familial pityriasis rubra pilaris (CR), 844
- histopathologic identification of dermal filler agents, 1072
- immunostains used in Mohs surgery, 760
- increased mast cell density in capecitabine-induced hand-foot syndrome (CR), 268
- intralesional interferon alfa-2b for BCC of nasal pyramid, 381
- isotretinoin-induced effects of mast cells on wound healing, 1207
- lichen planus pigmentosus (CR), 841
- localization and histology of injected hyaluronic acid in excised nasolabial fold tissue (CR), 399
- localized argyria secondary to acupuncture (CR), 1019
- macular hypomelanosis in pregnant African American woman with toxic nodular goiter (CR), 393
- Mohs surgery for melanoma in situ, 786
- nephrogenic systemic fibrosis, 829
- non-Hodgkin's B-cell lymphoma in a psoriatic patient (CR), 1277
- oral lichenoid drug reaction associated with anti-hypertensive and hypoglycemic drugs (CR), 73
- osteoinvasive subungual melanoma (CR), 159
- pancreatitis, panniculitis and polyarthritides syndrome (CR), 1145
- porokeratosis in patient with hepatitis of unclear etiology (CR), 258
- postpubertal eruptive syringoma triggered with antiepileptic drugs (CR), 707
- primary cutaneous angioimmunoblastic T-cell lymphoma (CR), 851
- rapid improvement of pyoderma gangrenosum after infliximab treatment (CR), 702
- sorafenib-induced psoriasiform eruption in patient with metastatic thyroid carcinoma (CR), 169
- TH17 in regression of metastatic melanoma to topical diphenylprone, 1368
- urticarial hypersensitivity reaction caused by temozolomide (CR), 1142
- Wong type dermatomyositis, 1475
- Histoplasmosis**, atypical presentation in a patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57
- Hodgkin's lymphoma**, development under bexarotene treatment for Sézary syndrome (CR), 1014
- Human immunodeficiency virus (HIV) disease**, monophasic, cohesive-polydensified-matrix crosslinking-technology-based HA filler for facial lipoatrophy in (CR), 690
- Human papillomavirus (HPV) vaccine**, FDA approves new indications for (PP), 80
- Hyaluronic acid (HA)**
- Belotero dermal filler close to FDA approval (PP), 1455
- effect of lidocaine when mixed with large gel particle hyaluronic acid filler on tolerability and longevity, 1097
- fillers for facial shaping, s129 (August)
- histopathologic identification of dermal filler agents, 1072
- hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for aesthetic rejuvenation therapy, 1135
- injection techniques for revolumization of perioral region with, 367
- localization and histology of injected hyaluronic acid in excised nasolabial fold tissue (CR), 399
- monophasic, cohesive-polydensified-matrix crosslinking-technology-based HA filler for facial lipoatrophy in HIV-infected patients (CR), 690
- Restylane and Perlane in correction of peri-oral wrinkles (CTR), 187
- tolerability and efficacy of novel formulation in treatment of melasma, 215
- treatment of facial atrophic scars with Esthélics, 1507
- treatment of forehead/glabellar rhytide complex with combination botulinum toxin A and hyaluronic acid vs. botulinum toxin injection alone (CTR), 1538
- Hydantoin**, drug-associated acne and acneiform eruptions, 627
- Hydrocortisone**
- hydrocortisone, silicone and vitamin E lotion for keloids and hypertrophic scars, 514
- pediatric indication for Locoid Lipocream® cream (PP), 80
- Hydrophilic molecules**, stratum corneum permeation and percutaneous drug delivery enhanced by cryopneumatic and photopneumatic technologies, 1528
- Hydroquinone**
- vs. azelaic acid in melasma (CTR), 727
- tolerability and efficacy of novel formulation in treatment of melasma, 215
- treating photodamage of décolletage area with novel copper zinc malonate complex plus tretinoin and, 220
- Hydroxychloroquine**
- efficacy in chronic urticaria (CTR), 1155
- successful treatment of perniosis with, 1242
- Hydroxyzine**, Mylan receives approval for hydroxyzine hydrochloride tablets (PP), 1160
- Hyperhidrosis**, practical applications of a new botulinum toxin, s31 (March)
- Hyperkeratosis**, efficacy and safety of new topical keratolytic treatment for, 1512
- Hypersensitivity reactions**. See also Drug reactions/toxicity
- fatal toxic epidermal necrolysis due to cardiac catheterization dye (CR), 837
- sublingual immunotherapy against latex sensitivity (PP), 183
- urticarial hypersensitivity reaction caused by temozolomide (CR), 1142
- Hypoglycemic drugs**, oral lichenoid drug reaction associated with antihypertensive drugs and (CR), 73
- Hypothalamic-pituitary-adrenal (HPA) axis**, safety and HPA axis effects of two-compound ointment containing calcipotriene/betamethasone dipropionate for psoriasis, 969
- Ichthyoses**, syndromic, novel treatment for (CTR), 1155
- Ichthyosis**, X-linked, steroid sulfatase gene deletion in Egyptian males with, 1192
- Idiopathic guttate hypomelanosis**, pimecrolimus for (BC), 238

- IDP-107**, safety and efficacy in patients with acne vulgaris (CTR), 1446
- IDP-108**, topical, safety and efficacy vs. vehicle in onychomycosis (CTR), 285, 577, 1538
- ILV-095**, evaluation of single dose in psoriasis subjects (CTR), 285, 577, 1035, 1446
- Imatinib**
drug-associated acne and acneiform eruptions, 627
in scleroderma (PP), 80
- Imiquimod cream**
for actinic keratoses, s45 (May)
development of subacute cutaneous lupus erythematosus associated with use of imiquimod to treat AK (CR), 1022
efficacy and safety study of 3.75% imiquimod cream following cryosurgery for AK, 1101
FDA approves Zyclara™ (PP), 723
generic approval of (PP), 572
for infantile hemangiomas (NVR), 176
medical and surgical management of keloids, 1249
Perrigo announces FDA approval for (PP), 1552
in treatment of morphea, 1213
- Immune function**
CTLA4-induced splenomegaly and literature review of autoimmune complications of therapy (CR), 1432
effect of pimecrolimus cream on cathelicidin levels in eczema (CTR), 883
impaired by corticosteroids for infantile hemangiomas (PP), 1033
isotretinoin-induced effects of mast cells on wound healing, 1207
statins in skin, 921
ustekinumab effects on primate/human antigen-recall and humoral immune response functions, 677
- Immunomodulators**
atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57
development of subacute cutaneous lupus erythematosus associated with use of imiquimod to treat AK (CR), 1022
drug-associated acne and acneiform eruptions, 627
etanercept for chronic urticaria (CTR), 1155
etanercept for familial pityriasis rubra pilaris (CR), 844
etanercept for recalcitrant cicatricial pemphigoid (CR), 68
etanercept in lichen planus (CTR), 187, 425, 577
generic approval of imiquimod cream 5% (PP), 572
how and when to use biologics in psoriasis, s106 (August)
injectable biologic and U0279 combination therapy for psoriasis (CTR), 285
long-term safety and efficacy of etanercept in psoriasis, 928
progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab (CR), 1005
prospective new biologic therapies for psoriasis and psoriatic arthritis, 947
rapid improvement of pyoderma gangrenosum after infliximab treatment (CR), 702
safety and effectiveness of etanercept for lichen planus of oral mucosa or skin (CTR), 577
safety and effectiveness of etanercept for lichen planus or oral mucosa or skin (CTR), 883
safety and efficacy of etanercept for discoid lupus erythematosus (CTR), 1538
- safety and efficacy of ustekinumab in psoriatic arthritis patients who have prior exposure to anti-TNF agents (CTR), 1155
safety study of clinical and immune effects of phosphodiesterase-4 inhibitor in cutaneous lupus (CTR), 1538
thalidomide and analogues, 814
use in biologic therapies in pediatric psoriasis, 975
ustekinumab vs. etanercept for psoriasis (PP), 572
- Immunosuppression**, multiple skin cancers in a patient on combination immunosuppressive therapy for Behçet's disease (CR), 152
- Immunotherapy**
dendritic cells and T cells in, 1383
dendritic cells in
potential role for complement in immune evasion by *Mycobacterium leprae*, 1373
role of complement in dendritic cell control of T-cell subsets (editorial), 1364
TH17 in regression of metastatic melanoma to topical diphencyprone, 1368
GSK2132231A antigen-specific immunotherapeutic in patients with inoperable metastatic cutaneous melanoma (CTR), 727, 1289
IV immunoglobulin therapy for scleromyxedema (CR), 263
MAGE-A3 antigen-specific cancer immunotherapeutic in patients with progressive metastatic cutaneous melanoma (CTR), 1289
sublingual, against latex sensitivity (PP), 183
- Impetigo**
impetigo herpetiformis in pregnancy (NVR), 1297
retapamulin vs. linezolid in treatment of SITL and impetigo due to MRSA (CTR), 82, 1538
- Incobotulinumtoxin A**. See also Botulinum toxin
FDA approves Merz Pharmaceuticals' Xeomin® (PP), 1455
- Incontinentia pigmenti**, delayed onychodystrophy of, 350
- Indoor tanning tax** (PP), 282
- Infantile hemangiomas**
current treatments for (NVR), 176
pulsed dual-wavelength 595 and 1064 nm in management of, 310
- Infection**
atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57
dermatologic emergencies (NVR), 1545
EPB-348 for herpes zoster (CTR), 1035
FDA Advisory Committee recommends approval of ceftaroline fosamil for (PP), 1552
FV-100 vs. valacyclovir for herpes zoster (CTR), 1035
management of guttate psoriasis and pityriasis rosea in patients with evidence of group A streptococcal infection (CR), 241
new agents for MRSA (NVR), 76
oral glutamine to suppress recurrent herpes labialis (CTR), 285
oregano-based ointment with antimicrobial activity against MRSA, 377
phase 3 study of torezolid phosphate for (PP), 1160
potential role for complement in immune evasion by *Mycobacterium leprae*, 1373
retapamulin vs. linezolid in treatment of SITL and impetigo due to MRSA (CTR), 82, 1538
safety and efficacy of CEM-102 vs. linezolid in bacterial skin infections (CTR), 1538
safety and pharmacokinetics of famciclovir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 285
- TR-701 for bacterial skin infections (CTR), 1538
using off-patent antibiotics for MRSA (CTR), 1538
- Inflammation**
anti-inflammatory effects of topical dapsone for acne, 667
effect of thalidomide on nitric oxide production in RAW 264.7 cells, 330
multifunctionality of 10% sodium sulfacetamide, 5% sulfur emollient foam in treatment of inflammatory facial dermatoses (BC), 234
properties of benzoyl peroxide, 482
thalidomide and analogues for immunomodulation of inflammatory and neoplastic disorders, 814
therapeutic shampoos for targeting symptoms of inflammatory scalp disorders, 41
- Infliximab**
atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57
drug-associated acne and acneiform eruptions, 627
how and when to use biologics in psoriasis, s106 (August)
rapid improvement of pyoderma gangrenosum after treatment with (CR), 702
use in pediatric psoriasis, 975
- Ingenol mebutate gel**, for actinic keratoses, s45 (May)
- Insulin injections**, cutaneous nontuberculous mycobacterial abscesses associated with (CR), 1439
- Integra**. See Collagen-glycosaminoglycan copolymer
- Intense pulsed light**, current guide to laser and light-based therapies for acne, 614
- Interferon**
Helix BioPharma and topical interferon alpha-2b for anogenital warts (PP), 723
interferon-alpha for infantile hemangiomas (NVR), 176
intralesional interferon alfa-2b for BCC of nasal pyramid, 381
medical and surgical management of keloids, 1249
PEG-interferon alfa-2b and UV light therapy in mycosis fungoides/Sézary syndrome (CTR), 883
pegylated interferon for children with high-risk melanoma (CTR), 727, 1289
- Interleukin-6**, effect of thalidomide on nitric oxide production in RAW 264.7 cells, 330
- Interleukin-12/23 inhibitors**
how and when to use biologics in psoriasis, s106 (August)
for psoriasis and psoriatic arthritis, 947
- Internet**
sales of isotretinoin (PP), 282
Sciton launches Japanese language website (PP), 1160
- Intrahepatic cholestasis of pregnancy** (NVR), 1297
- Intrauterine devices**, drug-associated acne and acneiform eruptions, 627
- Intravenous immunoglobulin (IVIG)**
with or without cyclophosphamide in pemphigus (CTR), 1289
for scleromyxedema (CR), 263
- Ipilimumab**
for metastatic melanoma (PP), 1160
in young patients with advanced or refractory solid tumors (CTR), 883
- Iraq**, prevalence of skin disease in deployed dermatology clinic in, 210
- Iressa®**. See Gefitinib

Iron overload and cutaneous disease (NVR), 719
Isoniazid, drug-associated acne and acneiform eruptions, 627
Isotretinoin
 AADA calls for FDA to address Internet sales of (PP), 282
 effects of mast cells on wound healing induced by, 1207
 inflammatory bowel disease and (NVR), 278
 as monotherapy for sebaceous hyperplasia (CR), 699
 trends in use for acne vulgaris, 519
Istodax[®]. See Romidepsin
Itraconazole
 comparison of SUBA[™]-itraconazole with SPO-RANOX[®] for onychomycosis (CTR), 187, 285, 425
 efficacy in BCC (CTR), 883, 1035

J
JC virus infection, progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab (CR), 1005

Juvederm
 Emervel Classic Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
 Emervel Deep Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
 Juvéderm[®] XC with lidocaine (PP), 418

K
Kalbitor. See Ecallantide
Keloids
 collagen-glycosaminoglycan copolymer for severe chest keloids, 542
 evidence-based appraisal of lasers for scars, 1355
 medical and surgical management of, 1249
 tolerability and efficacy of two topical therapies for, 514

Keratinocytes
 efficacy of hexapeptide-7 on menopausal skin, 49
 porokeratosis in patient with hepatitis of unclear etiology (CR), 258
Keratoacanthomas, 117
Kineret. See Anakinra

L
Lac-Hydrin[®] cream. See Ammonium lactate
Lamotrigine, drug-associated acne and acneiform eruptions, 627
Laser technology
 ablative fractional treatment of mature burn scars (CR), 389
 appearance of burn scar after CO2 fractional laser treatment (CTR), 727
 combination therapy for rosacea (CTR), 187, 285, 425, 1538
 comparison of RevLite Electro-optic Q-switched neodymium-doped yttrium aluminium garnet laser to a fractionated laser system (CTR), 82, 187, 425, 1035, 1155, 1289
 comparison of safety and efficacy of ALA plus a 532 nm KTP laser vs. 532 nm KTP laser alone for facial acne, 229
 current guide to laser and light-based therapies for acne, 614
 dual-wavelength laser lipolysis treatment of lipomas (CR), 387
 effects of fractional carbon dioxide laser treatment prior to wound closure (CTR), 1155
 effects of pulsed-dye laser on scar formation (CTR), 727, 1155

evidence-based appraisal of lasers for scars, 1355
 FDA 510(k) clearance of Fraxel re:store Dual Laser for AK (PP), 1552
 first fractional laser FDA cleared for stretch marks (PP), 418
 fractional photothermolysis for depressed alar scar following Mohs micrographic surgery (CR), 66
 Groove Optic[™] for Lux2940[™] for fractional skin resurfacing (PP), 183
 Hairmax Lasercomb for androgenetic alopecia in females (CTR), 1446
 laser lipolysis/lipolysis with 980 nm diode laser, s58 (May)
 laser treatment for fresh surgical scars and mature scars (CTR), 727, 1155
 medical and surgical management of keloids, 1249
 multi-wavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented skin lesions (CTR), 1035
 Nd:YAG laser for acne keloidalis nuchae (CTR), 569
 new SkinMedica ablative post-procedure kit (PP), 418
 onychomycosis therapy, 1109
 prospective study of improvement in periorbital wrinkles and eyebrow elevation with novel fractional CO2 laser—the fractional eyelift, 16
 pulsed dual-wavelength 595 and 1064 nm in management of hemangiomas, 310
 pulsed dye laser for infantile hemangiomas (NVR), 176
 Sciton launches better safety and more efficacy at annual meeting (PP), 418
 single-spot, 2940-nm Er:YAG dual-mode laser treatment of facial acne scars, 1341
 SmartLipo Triplex[™] for liposuction (PP), 80
 Solta Medical to buy Aesthera Corp. (PP), 418
 “tattoo blow-out” pigment spread treated with QS-Nd:YAG laser (CR), 1429
 tattoo treatment with alexandrite laser with two Nd:YAG laser handpieces pumped by alexandrite treatment beam, 1333
 treating onychomycosis (CTR), 187, 425, 1538
 treatment of androgenetic alopecia in females, 12 beam (CTR), 1446
 treatment of burn scar with CO2 fractional laser (CR), 173
 treatment of CO2 laser induced hypopigmentation with ablative fractionated laser resurfacing (CR), 1420
 treatment of melasma with topical creams alone, CO2 fractional ablative resurfacing alone, or combination of the two, 315
 treatment of surgical scars with pulsed dye laser (CTR), 727
 ultrapulsed fractional CO2 laser for post-traumatic and pathological scars, 1328
 Zerona now FDA-approved for body slimming (PP), 1455
Latanoprost, effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 1289
Latex sensitivity, sublingual immunotherapy against (PP), 183
LDE225, safety, local tolerability, pharmacokinetics, and pharmacodynamics on sporadic superficial skin BCC (CTR), 285, 883, 1035
Leech therapy, in cutaneous surgery and disease (CR), 252
Leiomyosarcoma, gemcitabine and docetaxel with or without bevacizumab in I malignant fibrous histiocytoma, angiosarcoma and (CTR), 285

Lenalidomide
 for generalized necrobiotic xanthogranuloma (CR), 273
 for mycosis fungoides/Sézary syndrome (CTR), 883
Leprosy, potential role for complement in immune evasion by *Mycobacterium leprae*, 1373
LEQ506, dose finding and safety study in patients with advanced solid tumors (CTR), 883
Letter from the Guest Editor, 104
Letters to the Editor, 602, 750, 751, 1059, 1475
Leukemia, dasatinib for unresectable or metastatic SCC or RAI stage 0–1 chronic lymphocytic leukemia (CTR), 883
Levetiracetam, reticulated drug eruption induced by (CR), 409
Levocetirizine
 for chronic idiopathic urticaria, 503
 for pruritus in atopic dermatitis (CTR), 82
Levodopa, phase 1 study of ND0611 dermal patch (PP), 1033
Levonorgestrel implants, drug-associated acne and acneiform eruptions, 627
Lice, benzyl alcohol lotion 5% for head lice (PP), 572
Lichen planus
 apremilast for (CTR), 577, 883
 cutaneous and mucosal, efficacy of metronidazole for, 1186
 etanercept in (CTR), 187, 425, 577
 lichen planus pigmentosus mimicking acral lentiginous melanoma (CR), 841
 oral lichenoid drug reaction associated with anti-hypertensive and hypoglycemic drugs (CR), 73
 of oral mucosa or skin, safety and effectiveness of etanercept for (CTR), 577, 883
Lidocaine
 effect of lidocaine when mixed with large gel particle hyaluronic acid filler on tolerability and longevity, 1097
 Emervel Classic Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
 Emervel Deep Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
 Juvéderm[®] XC with (PP), 418
 pain with Radiesse[®] with lidocaine for nasolabial folds (CTR), 577
 safety and efficacy of topical 4% lidocaine gel in unique drug delivery system, 1500
Light therapy, current guide to laser and light-based therapies for acne, 614
Linezolid
 versus CEM-102 in bacterial skin infections (CTR), 1538
 versus retapamulin in treatment of SITL and impetigo due to MRSA (CTR), 82, 1538
Lip
 lip tenting technique for augmentation of, 559
 PDT to treat actinic damage in patients with SCC of (CTR), 82, 1289
Lipoatrophy, monophasic, cohesive-polydensified-matrix crosslinking-technology-based HA filler for facial lipoatrophy in HIV-infected patients (CR), 690
Lipodissolve, FDA warning letters about claims regarding (PP), 874
Lipolysis
 with 980 nm diode laser, s58 (May)
 dual-wavelength laser lipolysis treatment of lipomas (CR), 387
Lipomas, dual-wavelength laser lipolysis treatment of (CR), 387
Liposuction, SmartLipo Triplex[™] for (PP), 80
Lithium, drug-associated acne and acneiform

- eruptions, 627
- Loratadine**, for chronic idiopathic urticaria, 503
- Lovastatin**, novel treatment for syndromic ichthyoses (CTR), 1155
- Luliconazole solution**, pharmacokinetics and safety in distal subungual onychomycosis (CTR), 577, 1155
- Lumigan**. See Bimatoprost
- Lupus erythematosus**
cutaneous
anti-TNF- α therapy and (CR), 1283
development associated with use of imiquimod to treat AK (CR), 1022
in pregnancy (NVR), 1297
safety and efficacy of etanercept for (CTR), 1538
safety study of clinical and immune effects of phosphodiesterase-4 inhibitor in (CTR), 1538
thalidomide and analogues for, 814
generalized systemic, atacept in (CTR), 1538
- Lymph nodes**
complete lymph node dissection or observation in treating patients with localized melanoma and sentinel node metastasis (CTR), 727
discussing sentinel lymph node biopsy with melanoma patients, 790
- M**
- Macular hypomelanosis**, in pregnant African American woman with toxic nodular goiter (CR), 393
- MAGE-A3 antigen-specific cancer immunotherapeutic**, in patients with progressive metastatic cutaneous melanoma (CTR), 1289
- Magnetic resonance imaging**, progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab (CR), 1005
- Malignant fibrous histiocytoma**, gemcitabine and docetaxel with or without bevacizumab in leiomyosarcoma, angiosarcoma and (CTR), 285
- Malignant proliferating trichilemmal tumor**, utilization of a new tissue expander in closure of large Mohs surgical defect (CR), 149
- Mast cells**, isotretinoin-induced effects on wound healing, 1207
- Mederma**[®], for stretch marks (PP), 418
- Medications in pregnancy** (NVR), 1297
- Melanoma**
Charcot-Marie-Tooth disease and multiple malignant melanomas (CR), 164
complete lymph node dissection or observation in treating patients with localized melanoma and sentinel node metastasis (CTR), 727
CTLA4-induced splenomegaly and literature review of autoimmune complications of therapy (CR), 1432
discussing sentinel lymph node biopsy with melanoma patients, 790
GSK2132231A antigen-specific immunotherapeutic in patients with inoperable metastatic cutaneous melanoma (CTR), 727, 1289
MAGE-A3 antigen-specific cancer immunotherapeutic in patients with progressive metastatic cutaneous melanoma (CTR), 1289
metastatic
ipilimumab for (PP), 1160
promising results of phase 1 trial of PLX4032 (PP), 1455
Mohs surgery for melanoma in situ, 786
multi-wavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented skin lesions (CTR), 1035
N-acetylcysteine to reduce risk of (PP), 183
new melanoma staging system (NVR), 1029
nilotinib in TKI resistant or intolerant patients with metastatic mucosal, acral, or chronically sundamaged melanoma (CTR), 883
osteoinvasive subungual (CR), 159
pegylated interferon for children with high-risk melanoma (CTR), 727, 1289
in pregnancy (NVR), 1297
TH17 in regression of metastatic melanoma to topical diphenylprone, 1368
thalidomide and analogues for, 814
unilateral lichen planus pigmentosus mimicking acral lentiginous melanoma (CR), 841
UV light exposure and immunosuppression in cutaneous melanoma (CTR), 1289
vaccine therapy in stage IV cutaneous melanoma (CTR), 1289
- Melasma**
azelaic acid vs. hydroquinone in (CTR), 727
tolerability and efficacy of novel formulation in treatment of, 215
treatment with topical creams alone, CO2 fractional ablative resurfacing alone, or combination of the two, 315
- Meningococemia** (NVR), 1545
- Mercury skin lightening cream**, FDA investigation of (PP), 1160
- Merkel cell carcinoma**, 779
management with emphasis on small primary tumors, 105
- Metformin**, in treatment of acne (NVR), 569
- Methotrexate**
efficacy and safety of adding methotrexate to etanercept in psoriasis (CTR), 82
in treatment of morphea, 1213
- Methylaminolevulinate (MAL)**
PDT with MAL cream in patients with skin type V or IV with acne (CTR), 187, 425
PDT with MAL without occlusion for acne vulgaris, 1347
- 4-Methylbenzylidene camphor**, sunscreen update: controversies, what's safe, what's next (NVR), 1451
- Metronidazole**
efficacy in treatment of cutaneous and mucosal lichen planus, 1186
efficacy of topical azelaic acid gel plus oral doxycycline vs. metronidazole gel plus oral doxycycline in rosacea, 607
- MGA031 (teplizumab)**, safety in subjects with moderate or more severe psoriasis (CTR), 82, 187, 425, 577
- Military personnel**, prevalence of skin disease in deployed dermatology clinic in Iraq, 210
- Minocycline**
acne relapse rate of oral minocycline vs. oral minocycline combined with topical tretinoin, followed by topical tretinoin alone (CTR), 577, 727
efficacy and safety of doxycycline and minocycline for acne, 1407
- Minoxidil**
for female pattern hair loss (CTR), 1446
vs. spironolactone pills in female pattern hair loss (CTR), 577
- Mohs micrographic surgery**
comparative efficacy and safety of topical hemostatic powder and sterile compressed foam sponge in second intention healing after, 137
flexible scalpel for minimally invasive and minimally scarring surgery for large scalp tumors, 1268
fractional photothermolysis for depressed alar scar following (CR), 66
immunostains used, 760
for melanoma in situ, 786
- rapid wound re-epithelialization and BCC clearance after Mohs micrographic surgery with postoperative PDT (CR), 143
rapid wound re-epithelialization and BCC clearance after Mohs surgery with postoperative PDT (RR), 878
utilization of a new tissue expander in closure of large Mohs surgical defect (CR), 149
- Moisturizers**
controlled multi-center study evaluating the efficacy of Vivate Skin Care for photoaging of face, eye and mouth, 22
and cosmeceuticals in clinical practice, s62 (May)
dapsona gel in combination with adapalene gel, benzoyl peroxide gel or moisturizer for acne vulgaris, 33
long-term efficacy and safety of topical PRK 124 lotion for rosacea, 647
- Mometasone furoate**, FDA approval of topical solution USP, 0.1% (PP), 1455
- Morphea**, treatment of, 1213
- Mortality risk**, tigecycline-associated (PP), 1455
- Multi-wavelength and coherence confocal reflectance microscopy**, of pigmented and nonpigmented skin lesions (CTR), 1035
- Mycobacterial infection**
cutaneous nontuberculous mycobacterial abscesses associated with insulin injections (CR), 1439
drug therapy for *M. ulcerans* infection, 341
potential role for complement in immune evasion by *M. leprae*, 1373
- Mycophenolate mofetil**, for chronic dermatitis, 356
- Mycosis fungoides/Sézary syndrome**
alemtuzumab followed by peripheral stem cell transplantation in (CTR), 883
development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome (CR), 1014
lenalidomide for (CTR), 883
PEG-interferon alfa-2b and UV light therapy in (CTR), 883
study of human monoclonal antibody zanolimumab for (CTR), 883
- N**
- NAB001**, safety and efficacy for onychomycosis of toenails (CTR), 1538
- Nail disorders**
antifungal activity and nail permeation of innovative ciclopirox nail lacquer, 525
comparison of SUBA[™]-itraconazole with SPORANOX[®] for onychomycosis (CTR), 187, 285, 425
delayed onychodystrophy of incontinentia pigmenti, 350
efficacy and safety of iontophoretic application of terbinafine gel in onychomycosis (CTR), 577, 1155
light therapy for toenail fungus (CTR), 285, 577, 1155
onychomycosis therapy, 1109
pharmacokinetics and safety of luliconazole solution in distal subungual onychomycosis (CTR), 577, 1155
rapid improvement in digital ischemia and acral contracture in collodion baby treated with topical tazarotene (CR), 713
safety and efficacy of NAB001 for onychomycosis of toenails (CTR), 1538
safety and efficacy of topical IDP-108 vs. vehicle in onychomycosis (CTR), 285, 577, 1538
study of effects of increasing doses of drug for

nail fungus (CTR), 187, 425
 TDT 067 onychomycosis study (CTR), 1538
 treating onychomycosis (CTR), 187, 425, 1538
Nalfurafine HCl (AC-820), safety and efficacy in subjects on hemodialysis with uremic pruritus (CTR), 82
Nanotechnology
 dermal effects of nanoparticles, 475
 nanotechnology and the Nanodermatology Society (IC), 879
 sunscreen update: controversies, what's safe, what's next (NVR), 1451
 as topical therapeutic strategy for vascular dysfunction (RR), 574
Neck and face revitalization, with platelet-rich plasma, 466
Necrobiotic xanthogranuloma, generalized, lenalidomide for (CR), 273
Necrotizing fasciitis, drug therapy for, 341
Necrotizing vasculitis, drug therapy for, 341
Neoplasia
 ALA-PDT vs. vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 82
 alemtuzumab followed by peripheral stem cell transplantation in advanced mycosis fungoides/Sézary syndrome (CTR), 883
 bevacizumab for angiosarcoma (CTR), 285
 bimatoprost ophthalmic solution in promoting eyebrow and eyelash hair growth in breast cancer patients (CTR), 82, 577
 BMS-833923 (XL139) in advanced or metastatic cancer (CTR), 883, 1035
 celecoxib inhibition of genetic BCC (PP), 418
 Charcot-Marie-Tooth disease and multiple malignant melanomas (CR), 164
 complete lymph node dissection or observation in treating patients with localized melanoma and sentinel node metastasis (CTR), 727
 correlation between skin carotenoid levels and previous history of skin cancer (CTR), 1289
 CTLA4-induced splenomegaly and literature review of autoimmune complications of therapy (CR), 1432
 current treatments for infantile hemangiomas (NVR), 176
 dasatinib for unresectable or metastatic SCC (CTR), 285
 dasatinib for unresectable or metastatic SCC or RAI stage 0-1 chronic lymphocytic leukemia (CTR), 883
 dermoscopy impact on skin cancer diagnostics, 129
 development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome (CR), 1014
 discussing sentinel lymph node biopsy with melanoma patients, 790
 dose finding and safety study of oral LEQ506 in patients with advanced solid tumors (CTR), 883
 dual-wavelength laser lipolysis treatment of lipomas (CR), 387
 efficacy and safety of GDC-0449 in patients with advanced BCC (CTR), 82, 285
 efficacy of itraconazole in BCC (CTR), 883, 1035
 efficacy of PDT for recurrent SCC and BCC, 122
 electrocauterization and curettage vs. excision for SCC, 773
 electronic brachytherapy for non-melanoma skin cancer (CTR), 1035
 erlotinib and radiotherapy for cutaneous SCC (CTR), 82, 285
 erlotinib in women with SCC of vulva (CTR), 1289

erlotinib prior to surgery of radiation in patients with SCC (CTR), 883
 flexible scalpel for minimally invasive and minimally scarring surgery for large scalp tumors, 1268
 gemcitabine and docetaxel with or without bevacizumab in leiomyosarcoma, malignant fibrous histiocytoma and angiosarcoma (CTR), 285
 GSK2132231A antigen-specific immunotherapeutic in patients with inoperable metastatic cutaneous melanoma (CTR), 727, 1289
 human monoclonal antibody zanolimumab to treat mycosis fungoides/Sézary syndrome (CTR), 883
 intralesional interferon alfa-2b for BCC of nasal pyramid, 381
 ipilimumab for metastatic melanoma (PP), 1160
 ipilimumab in young patients with advanced or refractory solid tumors (CTR), 883
 Istdox for cutaneous T-cell lymphoma (PP), 183
 keratoacanthomas, 117
 lenalidomide for mycosis fungoides/Sézary syndrome (CTR), 883
 MAGE-A3 antigen-specific cancer immunotherapeutic in patients with progressive metastatic cutaneous melanoma (CTR), 1289
 management of Merkel cell carcinoma with emphasis on small primary tumors, 105
 Merkel cell carcinoma, 779
 Mohs surgery for melanoma in situ, 786
 multiple skin cancers in a patient on combination immunosuppressive therapy for Behçet's disease (CR), 152
 multi-wavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented skin lesions (CTR), 1035
 N-acetylcysteine to reduce melanoma risk (PP), 183
 new melanoma staging system (NVR), 1029
 nilotinib in TKI resistant or intolerant patients with metastatic mucosal, acral, or chronically sundamaged melanoma (CTR), 883
 non-Hodgkin's B-cell lymphoma in a psoriatic patient (CR), 1277
 osteoinvasive subungual melanoma (CR), 159
 patient with nevoid BCC syndrome treated successfully with PDT (CR), 167
 PDT to treat actinic damage in patients with SCC of lip (CTR), 82, 1289
 PDT using ALA in treating patients with skin cancer (CTR), 82
 PEG-interferon alfa-2b and UV light therapy in mycosis fungoides/Sézary syndrome (CTR), 883
 pegylated interferon for children with high-risk melanoma (CTR), 727, 1289
 population education in preventing skin cancer: from childhood to adulthood, 112
 in pregnancy (NVR), 1297
 promising results of metastatic melanoma phase 1 trial of PLX4032 (PP), 1455
 rapid wound re-epithelialization and BCC clearance after Mohs micrographic surgery with postoperative PDT (CR), 143
 rapid wound re-epithelialization and BCC clearance after Mohs surgery with postoperative PDT (RR), 878
 role of phototherapy in cutaneous T-cell lymphoma, 764
 maintenance phototherapy, 800
 safety, local tolerability, pharmacokinetics, and pharmacodynamics of LDE225 on sporadic superficial skin BCC (CTR), 285, 883, 1035
 sorafenib-induced psoriasiform eruption in

patient with metastatic thyroid carcinoma (CR), 169
 successful treatment of cutaneous T-cell lymphoma with topical 5-fluorouracil (CR), 1017
 systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients, 753
 TH17 in regression of metastatic melanoma to topical diphencyprone, 1368
 thalidomide and analogues for immunomodulation of inflammatory and neoplastic disorders, 814
 trial of Dermacorder for detecting malignant skin lesions (CTR), 883
 UV light exposure and immunosuppression in cutaneous melanoma (CTR), 1289
 vaccine therapy in stage IV cutaneous melanoma (CTR), 1289
 ZD1839 for recurrent or metastatic SCC of skin (CTR), 883
Nephrogenic systemic fibrosis, 829
News, Views, and Reviews (NVR), 76, 176, 278, 412, 569, 719, 871, 1029, 1297, 1451, 1545
Niacinamide, cosmeceuticals in clinical practice, s62 (May)
Nigerian plants, for cancer-related alopecia, 537
Nilotinib, in TKI resistant or intolerant patients with metastatic mucosal, acral, or chronically sundamaged melanoma (CTR), 883
Nitric oxide, effect of thalidomide on production in RAW 264.7 cells, 330

O

Ocular cicatricial pemphigoid
 etanercept for (CR), 68
 rituximab in (CTR), 187, 425, 577, 1289
Omalizumab, efficacy and safety in bullous pemphigoid (CTR), 187, 425, 577, 1289
Onion extract gel, for keloids and hypertrophic scars, 514
Onion juice, for alopecia, 537
Onychodystrophy, delayed, of incontinentia pigmenti, 350
Onychomycosis
 antifungal activity and nail permeation of innovative ciclopirox nail lacquer, 525
 comparison of SUBA™-itraconazole with SPO-RANOX® for (CTR), 187, 285, 425
 efficacy and safety of iontophoretic application of terbinafine gel in (CTR), 577, 1155
 light therapy for (CTR), 285, 577, 1155
 pharmacokinetics and safety of luliconazole solution in (CTR), 577, 1155
 safety and efficacy of NAB001 for onychomycosis of toenails (CTR), 1538
 safety and efficacy of topical IDP-108 vs. vehicle in (CTR), 285, 577, 1538
 study of effects of increasing doses of drug for nail fungus (CTR), 187, 425
 TDT 067 study (CTR), 1538
 therapy for, 1109
 treatment of (CTR), 187, 425, 1538
Oral contraceptives, trends in use for acne vulgaris, 519
Oral lesions
 etanercept for recalcitrant cicatricial pemphigoid (CR), 68
 oral glutamine to suppress recurrent herpes labialis (CTR), 285
 oral lichenoid drug reaction associated with anti-hypertensive and hypoglycemic drugs (CR), 73
 retinoids for palliative treatment of paraneoplastic acanthosis nigricans and oral florid papillomatosis (CR), 1151

safety and effectiveness of etanercept for lichen planus of oral mucosa or skin (CTR), 577, 883
safety and pharmacokinetics of famciclovir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 285

Oregano-based ointment, with antimicrobial activity against MRSA, 377

Oseltamivir (NVR), 76

Osteoinvasive subungual melanoma (CR), 159

Oxandrolone, in treatment of decubitus ulcers (CR), 711

Oxidative stress

dose-dependent antioxidant function of resveratrol, 1523

efficacy and tolerance of novel phenolic antioxidant skin care system, 1480

oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11

Oxybenzone, sunscreen update: controversies, what's safe, what's next (NVR), 1451

P

P-3051, antifungal activity and nail permeation of innovative ciclopirox nail lacquer, 525

Pain, with Radiesse® with lidocaine for nasolabial folds (CTR), 577

Palmoplantar keratoderma, efficacy and safety of topical keratolytic treatment for, 1512

Palmyitoyethanolamide-containing cream, for atopic dermatitis, 334

Pancreatitis, panniculitis and polyarthritis syndrome (CR), 1145

Panicum miliaceum, for cancer-related alopecia, 537

Panitumumab, cutaneous reactions to epidermal growth factor receptor inhibitors, 1229

Paraffin, histopathologic identification of dermal filler agents, 1072

Parasitosis, delusions of, aripiprazole for (CR), 1531

Parkinson's disease, phase 1 study of ND0611 dermal patch (PP), 1033

Patient education, approaching psoriasis: patient-physician relationships, patient education and choosing the right topical vehicle, 908

Pediatric dermatology

corticosteroids for infantile hemangiomas impair immune function (PP), 1033

current treatments for infantile hemangiomas (NVR), 176

dermatologic indicators of eating disorders (NVR), 412

Epiduo® pediatric acne study (CTR), 1155

novel treatment for syndromic ichthyoses (CTR), 1155

pediatric indication for Locoid Lipocream® cream (PP), 80

pediatric longitudinal evaluation of long-term safety of Protopic® for atopic dermatitis (CTR), 1446

pegylated interferon for children with high-risk melanoma (CTR), 727, 1289

population education in preventing skin cancer: from childhood to adulthood, 112

pulsed dual-wavelength 595 and 1064 nm in management of hemangiomas, 310

rapid improvement in digital ischemia and acral contracture in collodion baby treated with topical tazarotene (CR), 713

safety and pharmacokinetics of famciclovir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 285

topical tretinoin gel and acne in preadolescents (PP), 1033

topical vitamin B12 for childhood atopic dermatitis (CTR), 1155, 1446

use of biologic agents in pediatric psoriasis, 975
voriconazole-induced photosensitivity/photoaging in X-linked chronic granulomatous disease (CR), 562

PEG-interferon alfa-2b, and UV light therapy in mycosis fungoides/Sézary syndrome (CTR), 883

Pemphigoid

bullous, efficacy and safety of omalizumab in (CTR), 187, 425, 577, 1289

etanercept for recalcitrant cicatricial pemphigoid (CR), 68

rituximab in ocular cicatricial pemphigoid (CTR), 187, 425, 577, 1289

Pemphigus vulgaris

IVIg with or without cyclophosphamide in (CTR), 1289

pimecrolimus cream for cutaneous lesions of, 684

Perililyl alcohol, topical, in treating patients with sun damaged skin and AK (CTR), 82

Perioral region, injection techniques for revolumization with hyaluronic acid, 367

Periorbital region

controlled multi-center study evaluating the efficacy of Vivité Skin Care for photoaging of face, eye and mouth, 22

effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 1289

minimally invasive techniques for periorbital rejuvenation, s118 (August)

novel sonic infusion system for periorbital rhytides, 1121

prospective study of improvement in periorbital wrinkles and eyebrow elevation with novel fractional CO2 laser—the fractional eyelift, 16

Peripheral artery disease

combination stem cell therapy for treatment of severe leg ischemia (CTR), 1289

safety of adult stem cells to treat patients with severe leg artery disease (CTR), 1289

Pemiosis, successful treatment with hydroxychloroquine, 1242

Pharmacokinetics

safety and pharmacokinetics of famciclovir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 285

safety and pharmacokinetics of new formulation of bimatoprost in alopecia (CTR), 1446

safety, local tolerability, pharmacokinetics, and pharmacodynamics of LDE225 on sporadic superficial skin BCC (CTR), 285, 883, 1035

and safety of luliconazole solution in distal subungual onychomycosis (CTR), 577, 1155

Phosphodiesterase-4 inhibitor, safety study of clinical and immune effects in cutaneous lupus (CTR), 1538

Photoaging. See also Cutaneous aging
comparison of RevLite Electro-optic Q-switched neodymium-doped yttrium aluminium garnet laser to a fractionated laser system (CTR), 82, 187, 425, 1035, 1155, 1289

controlled multi-center study evaluating the efficacy of Vivité Skin Care for photoaging of face, eye and mouth, 22

efficacy and tolerance of novel phenolic antioxidant skin care system for, 1480

MyoScience Tissue Remodeling Device for facial rejuvenation (CTR), 577

Restylane and Perlane in correction of peri-oral wrinkles (CTR), 187

topical perililyl alcohol in treating patients with sun damaged skin and AK (CTR), 82

topically dissolved oxygen (TDO) to ameliorate signs of photodamage (CTR), 187, 425

treating photodamage of décolletage area with novel copper zinc malonate complex plus hydroquinone and tretinoin, 220

voriconazole-induced photosensitivity/photoaging in X-linked chronic granulomatous disease (CR), 562

Photodynamic therapy (PDT)

for actinic keratoses, s45 (May)

ALA-PDT for cutaneous pseudolymphoma (CR), 688

ALA-PDT vs. vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 82

comparison of safety and efficacy of ALA plus a 532 nm KTP laser vs. 532 nm KTP laser alone for facial acne, 229

current guide to laser and light-based therapies for acne, 614

efficacy and safety of Visonac PDT for acne (CTR), 1155, 1289, 1446

efficacy for recurrent SCC and BCC, 122

patient with nevoid BCC syndrome treated successfully with (CR), 167

PDT with MAL cream in patients with skin type V or IV with acne (CTR), 187, 425

PDT with MAL without occlusion for acne vulgaris, 1347

rapid wound re-epithelialization and BCC clearance after Mohs micrographic surgery with postoperative PDT (CR), 143

rapid wound re-epithelialization and BCC clearance after Mohs surgery with postoperative PDT (RR), 878

to treat actinic damage in patients with SCC of lip (CTR), 82, 1289

in treatment of morphea, 1213

using ALA in treating patients with skin cancer (CTR), 82

utilizing combination or sequential treatment with 5-fluorouracil cream and destructive treatments (CR), 864

Photopneumatic technology, stratum corneum permeation and percutaneous drug delivery of hydrophilic molecules enhanced by, 1528

Photosensitivity, voriconazole-induced photosensitivity/photoaging in X-linked chronic granulomatous disease (CR), 562

Phototherapy

current guide to laser and light-based therapies for acne, 614

light therapy to treat toe nail fungus (CTR), 285, 577, 1155

PEG-interferon alfa-2b and UV light therapy in mycosis fungoides/Sézary syndrome (CTR), 883

role in cutaneous T-cell lymphoma, 764

for toenail fungus (CTR), 285, 577

in treatment of morphea, 1213

usefulness of narrowband UVB as monotherapy for chronic plaque psoriasis, 989

Pigmentation

azelaic acid vs. hydroquinone in melasma (CTR), 727

effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 1289

failure of botulinum toxin treatment for localized vitiligo, 1092

localized argyria secondary to acupuncture (CR), 1019

macular hypomelanosis in pregnant African American woman with toxic nodular goiter (CR), 393

pimecrolimus for idiopathic guttate hypomelanosis (BC), 238
 tolerability and efficacy of novel formulation in treatment of melasma, 215
 treatment of CO₂ laser induced hypopigmentation with ablative fractionated laser resurfacing (CR), 1420
 treatment of melasma with topical creams alone, CO₂ fractional ablative resurfacing alone, or combination of the two, 315
 unilateral lichen planus pigmentosus mimicking acral lentiginous melanoma (CR), 841

Pimecrolimus
 cost-effectiveness vs. tacrolimus ointment for atopic dermatitis, 372
 for cutaneous lesions of pemphigus vulgaris, 684
 effect on cathelicidin levels in eczema (CTR), 883
 for idiopathic guttate hypomelanosis (BC), 238
 versus tacrolimus for pruritus in atopic dermatitis, 488

Pipeline Previews (PP)
 AADA calls for FDA to address Internet sales of isotretinoin, 282
 AADA endorses Senate's proposed indoor tanning tax, 282
 AccuView digital imaging system, 418
 antioxidant N-acetylcysteine to reduce melanoma risk, 183
 Belotero dermal filler close to FDA approval, 1455
 benzoyl peroxide-clindamycin combinations and skin hydration, 80
 benzyl alcohol lotion 5% for head lice, 572
 Biopelle secures rights to distribute Heliocare®, 183
 botulinum toxin type A reduces itch, 282
 Canfield introduces new facial 3D imaging system, 418
 celecoxib inhibition of genetic BCC, 418
 Clinuvel Pharmaceuticals gets FDA approval for light intolerance drug trial, 723
 corticosteroids for infantile hemangiomas impair immune function, 1033
 efalizumab for resistant plaque psoriasis, 183
 Ertaczo® relieves itching, 80
 FDA 510(k) clearance of Fraxel re:store Dual Laser for AK, 1552
 FDA Advisory Committee recommends approval of ceftaroline fosamil, 1552
 FDA approval of ecallantide for hereditary angioedema, 572
 FDA approval of e-Matrix device, 572
 FDA approval of Istdox for cutaneous T-cell lymphoma, 183
 FDA approval of mometasone furoate topical solution USP, 0.1%, 1455
 Fda approves Exilis body shaping as nonsurgical device, 874
 FDA approves Glenmark's calcipotriene ointment, 723
 FDA approves Juvéderm® XC with lidocaine, 418
 FDA approves Merz Pharmaceuticals' Xeomin®, 1455
 FDA approves new indications for HPV vaccine, 80
 FDA approves polidocanol for small varicose veins, 723
 FDA approves Qutenza® for postherpetic neuralgia, 282
 FDA approves Ulthera's ultrasound product, 282
 FDA approves Zyclara™, 723
 FDA clearance of V.A.C. therapy for venous insufficiency ulcers, 1160
 FDA issues warning letters about claims regarding lipodissolve, 874
 FDA panel makes tanning bed recommendations,

874
 FDA reviewing safety of antibacterial soap ingredient triclosan, 874
 FDA warns consumers in Puerto Rico of harmful bacteria in hand sanitizers, 874
 FDA widens mercury skin lightening cream investigation, 1160
 first fractional laser FDA cleared for stretch marks, 418
 Galderma receives approval for Differin® (adapalene) lotion 0.1%, 723
 generic approval of adapalene cream 0.1%, 1160
 generic approval of imiquimod cream 5%, 572
 Groove Optic™ for Lux2940™ for fractional skin resurfacing, 183
 Helix BioPharma and topical interferon alpha-2b, 723
 high resolution ultrasound helps in diagnosis of blue skin lesions, 1160
 imatinib in scleroderma, 80
 ipilimumab for metastatic melanoma, 1160
 Iredale Mineral Cosmetics receives Seal of Recommendation from Skin Cancer Foundation, 572
 Mederma® for stretch marks, 418
 Mylan receives approval for generic Valtrex®, 1033
 Mylan receives approval for hydroxyzine hydrochloride tablets, 1160
 new SkinMedica ablative post-procedure kit, 418
 new study implicates autoimmune mechanisms in alopecia areata, 1160
 pediatric indication for Locoid Lipocream® cream, 80
 Perrigo announces FDA approval for imiquimod cream, 1552
 phase 1 study of ND0611 dermal patch, 1033
 positive phase 2b clinical trial of psoriasis drug apremilast, 282
 promising results of metastatic melanoma phase 1 trial of PLX4032, 1455
 prompt biological therapy speeds diabetic foot ulcer healing, 1455
 PureGraft™ System receives marketing clearance, 723
 sales of Basilea's antibiotic Zeftera stopped in Canada, 874
 Sanofi Pasteur and Syntiron, 282
 Sciton launches better safety and more efficacy at annual meeting, 418
 Sciton launches Japanese language website to enhance customer experience, 1160
 SkinMedical launches new Rejuvenize Peel™, 418
 SmartLipo Triplex™ for liposuction, 80
 Soligenix study of orBec® for prevention of GVHD (PP), 1033
 Solta Medical to buy Aesthera Corp., 418
 Stelara (ustekinumab) vs. etanercept for psoriasis, 572
 tigecycline linked to increased mortality risk, 1455
 topical tretinoin gel and acne in preadolescents, 1033
 Trius Therapeutics phase 3 study of torezolid phosphate, 1160
 Zeltiq receives FDA clearance, 1552
 Zerona now FDA-approved for body slimming, 1455

Pityriasis rosea, management of guttate psoriasis and pityriasis rosea in patients with evidence of group A streptococcal infection (CR), 241
Pityriasis rubra pilaris, familial (CR), 844
Platelet-rich plasma (PRP), face and neck revitalization with, 466
PLX4032, promising results of metastatic melanoma phase 1 trial (PP), 1455

Polidocanol
 approval for sclerotherapy (NVR), 871
 FDA approval for small varicose veins (PP), 723

Poly-L-lactic acid (PLLA)
 fillers for facial shaping, s129 (August)
 histopathologic identification of dermal filler agents, 1072
 use in people of color, 451

Polymethylmethacrylate/bovine collagen, histopathologic identification of dermal filler agents, 1072

Polymethylmethacrylate/carboxygluconate, histopathologic identification of dermal filler agents, 1072

Population education, in preventing skin cancer: from childhood to adulthood, 112

Porokeratosis, in patient with hepatitis of unclear etiology (CR), 258

Porphyria cutanea tarda (NVR), 719

Postherpetic neuralgia, FDA approves Qutenza® for (PP), 282

Potassium titanyl phosphate laser, current guide to laser and light-based therapies for acne, 614

Pregnancy
 dermatology in (NVR), 1297
 macular hypomelanosis in pregnant African American woman with toxic nodular goiter (CR), 393

Pressure ulcers, oxandrolone treatment of (CR), 711

Prevention
 ALA-PDT versus vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 82
 population education in preventing skin cancer: from childhood to adulthood, 112
 Soligenix study of orBec® for prevention of GVHD (PP), 1033
 systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients, 753
 topical cidofovir for prevention of hair growth (CTR), 82

Primula, for alopecia, 537

PRK 124 lotion, long-term efficacy and safety in rosacea, 647

Procyanidins, for alopecia, 537

Progressive multifocal leukoencephalopathy, in two psoriasis patients treated with efalizumab (CR), 1005

Propranolol, for infantile hemangiomas (NVR), 176

Prostaglandin eye drops, effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 1289

Protopic®, pediatric longitudinal evaluation of long-term safety for atopic dermatitis (CTR), 1446

Provenge (Sipuleucel-T), role of complement in dendritic cell control of T-cell subsets (editorial), 1364

Prurigo of pregnancy (NVR), 1297

Pruritic folliculitis of pregnancy (NVR), 1297

Pruritus
 in atopic dermatitis, 488
 botulinum toxin type A reduces itch (PP), 282
 efficacy of topical antihistamines for, 992
 Ertaczo® for (PP), 80
 management with Xyzal in atopic dermatitis (CTR), 82
 in pregnancy (NVR), 1297
 safety and efficacy of oral nalfurafine HCl (AC-820) in subjects on hemodialysis with uremic pruritus (CTR), 82

Psoralen-UVA, drug-associated acne and acneiform eruptions, 627

Psoriasis

AIN457 regimen finding study in (CTR), 285
alefacept treatment for up to one year, 1491
atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57
bicillin LA versus placebo for psoriasis unresponsive to topical medications (CTR), 425
botulinum toxin for (CTR), 82, 1033
bupropion-induced Stevens-Johnson syndrome with acute psoriatic exacerbation (CR), 1010
clinical activity, safety, and tolerability of SRT2104 in subjects with (CTR), 1446
dose finding study of AEB071 assessing psoriasis area and severity index in patients with (CTR), 285
efalizumab for resistant plaque (PP), 183
efficacy and safety of adding methotrexate to etanercept in (CTR), 82
efficacy and safety of ASP015K in (CTR), 1033, 1446
efficacy of 15% azelaic acid in, 964
efficacy of Ultravate ointment in combination with Lac-Hydrin cream for (CTR), 285, 577, 1033
erlotinib for (CTR), 82, 187, 285, 425, 577, 1033, 1446
evaluation of single dose of ILV-095 in subjects with (CTR), 285, 577, 1033, 1446
evidence-based review of coal tar preparations for, 1258
FDA approves Glenmark's calcipotriene ointment for (PP), 723
fluphenazine hydrochloride for (CTR), 187, 425, 1446
how and when to use biologics in, s106 (August)
injectable biologic and U0279 combination therapy for (CTR), 285
long-term safety and efficacy of etanercept in, 928
management of guttate psoriasis and pityriasis rosea in patients with evidence of group A streptococcal infection (CR), 241
non-Hodgkin's B-cell lymphoma in a psoriatic patient (CR), 1277
patient-physician relationships, patient education and choosing the right topical vehicle, 908
positive phase 2b clinical trial of apremilast for (PP), 282
in pregnancy (NVR), 1297
progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab (CR), 1005
prospective new biologic therapies for psoriatic arthritis and, 947
safety and efficacy of BFH772 in patients with (CTR), 187, 425
safety and HPA axis effects of two-compound ointment containing calcipotriene/betamethasone dipropionate for, 969
safety of teplizumab (MGA031) in subjects with moderate or more severe psoriasis (CTR), 82, 187, 425, 577
scalp, 912, s101 (August)
thalidomide and analogues for, 814
therapeutic shampoos for targeting symptoms of inflammatory scalp disorders, 41
treatment in alcoholics (CR), 405
treatment patterns and perceptions of treatment attributes, satisfaction and effectiveness among patients with, 938
use of biologic agents in pediatric patients with, 975
usefulness of narrowband UVB as monotherapy

for chronic plaque psoriasis, 989
ustekinumab versus etanercept for (PP), 572
VB-201 for (CTR), 1033, 1446
Psoriatic arthritis
adult onset, certolizumab pegol for (CTR), 1446
atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57
prospective new biologic therapies for psoriasis and, 947
safety and efficacy of ustekinumab in patients who have prior exposure to anti-TNF agents (CTR), 1155
Psychosocial sequelae of acne, s50 (May)
Pulsed dye laser
combination therapy for rosacea (CTR), 187, 285, 425, 1538
current guide to laser and light-based therapies for acne, 614
effect on scar formation (CTR), 1155
for infantile hemangiomas (NVR), 176
treatment of surgical scars with (CTR), 727
Purging behavior, dermatologic indicators of (NVR), 412
Purpura fulminans, drug therapy for, 341
Pycnogenol, oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11
Pyoderma gangrenosum, drug therapy for, 341
Pyoderma gangrenosum, rapid improvement after infliximab treatment (CR), 702
Pyratine-XR. See PRK 124 lotion

Q

Quinidine, drug-associated acne and acneiform eruptions, 627
Qutenza[®]. See Capsaicin

R

Race/ethnicity
attaining predictable aesthetic results with dermal fillers, 458
macular hypomelanosis in pregnant African American woman with toxic nodular goiter (CR), 393
use of injectable poly-L-lactic acid in people of color, 451
Radiation therapy
and erlotinib for cutaneous SCC (CTR), 82, 285
erlotinib prior to surgery or radiation in patients with SCC (CTR), 883, 1289
medical and surgical management of keloids, 1249
Radiesse[®]. See Calcium hydroxylapatite
Raspberry ketone, for alopecia, 537
Red man syndrome (NVR), 76
Rejuvenize Peel[™] (PP), 418
Relaxation strategies, for patients during dermatologic surgery, 795
Remicade[®]. See Infliximab
Renal disease
drug therapy for calciphylaxis, 341
nephrogenic systemic fibrosis, 829
safety and efficacy of oral nalfurafine HCl (AC-820) in subjects on hemodialysis with uremic pruritus (CTR), 82
warfarin-induced skin necrosis mimicking calciphylaxis (CR), 859
Resident Rounds, 574, 725, 878
Restasis. See Cyclosporin ophthalmic solution
Restylane. See Hyaluronic acid
Resveratrol, dose-dependent antioxidant function of, 1523

Retapamulin

in age of *S. aureus* antimicrobial resistance, 1198
versus linezolid in treatment of SITL and impetigo due to MRSA (CTR), 82, 1538
treatment of atopic dermatitis with concurrent Altabax[®] and topical low-potency corticosteroids versus low-potency corticosteroid monotherapy (CTR), 883, 1033

Retinoids

AADA calls for FDA to address Internet sales of isotretinoin (PP), 282
acne relapse rate of oral minocycline versus oral minocycline combined with topical tretinoin, followed by topical tretinoin alone (CTR), 577, 727
antimicrobial efficacy of benzoyl peroxide/clindamycin phosphate gel versus clindamycin phosphate/tretinoin gel for acne vulgaris, 131
Atralin gel for rosacea (CTR), 1033, 1538
irritation potential of tretinoin gel microsphere pump versus adapalene plus benzoyl peroxide gel, 998
isotretinoin and inflammatory bowel disease and (NVR), 278
isotretinoin as monotherapy for sebaceous hyperplasia (CR), 699
isotretinoin-induced effects of mast cells on wound healing, 1207
morning/morning regimen of tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for acne, 805
optimizing acne therapy with unique vehicles, s53 (May)
oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11
for palliative treatment of paraneoplastic acanthosis nigricans and oral florid papillomatosis (CR), 1151
safety and efficacy of clindamycin and tretinoin gel for rosacea (CTR), 187, 285, 425, 1033
sunscreens update: controversies, what's safe, what's next (NVR), 1446
systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients, 753
topical tretinoin gel and acne in preadolescents (PP), 1033
treating photodamage of décolletage area with novel copper zinc malonate complex plus hydroquinone and tretinoin, 220
trends in use for acne vulgaris, 519
Rifampicin, drug-associated acne and acneiform eruptions, 627
Rituximab, in ocular cicatricial pemphigoid (CTR), 187, 425, 577, 1289
Rocky Mountain spotted fever (NVR), 1545
Romidepsin, for cutaneous T-cell lymphoma (PP), 183
Rosacea
apremilast for (CTR), 727, 1033, 1538
Atralin gel for (CTR), 1033, 1538
changes in comorbidities and treatment utilization over time, 1402
combination therapy for (CTR), 187, 285, 425, 1538
efficacy and safety of CD07805/47 gel in subjects with facial erythema associated with (CTR), 1538
efficacy of topical azelaic acid gel plus oral doxycycline versus metronidazole gel plus oral doxycycline in, 607
long-term efficacy and safety of topical PRK 124 lotion for, 647
safety and efficacy of clindamycin and tretinoin gel for (CTR), 187, 285, 425, 1033, 1538

topical cyclosporin for ocular rosacea (CTR), 285
we are making progress with acne and rosacea (editorial), 603

S

Safety issues

clinical activity, safety, and tolerability of SRT2104 in subjects with psoriasis (CTR), 1446
comparative efficacy and safety of topical hemostatic powder and sterile compressed foam sponge in second intention healing after Mohs micrographic surgery, 137
comparison of safety and efficacy of ALA plus a 532 nm KTP laser versus 532 nm KTP laser alone for facial acne, 229
dapsona gel in combination with adapalene gel, benzoyl peroxide gel or moisturizer for acne vulgaris, 33
dose finding and safety study of oral LEQ506 in patients with advanced solid tumors (CTR), 883
efficacy and safety of adding methotrexate to etanercept in psoriasis (CTR), 82
efficacy and safety of ASP015K in psoriasis (CTR), 1033, 1446
efficacy and safety of CD07223 gel in subjects with acne (CTR), 1446
efficacy and safety of CD07805/47 gel in subjects with facial erythema associated with rosacea (CTR), 1538
efficacy and safety of doxycycline and minocycline for acne, 1407
efficacy and safety of fixed-dose adapalene-benzoyl peroxide combination gel for acne in adolescents, 1395
efficacy and safety of GDC-0449 in patients with advanced BCC (CTR), 82, 285
efficacy and safety of iontophoretic application of terbinafine gel in onychomycosis (CTR), 577, 1155
efficacy and safety of new topical keratolytic treatment for hyperkeratosis, 1512
efficacy and safety of omalizumab in bullous pemphigoid (CTR), 187, 425, 577, 1289
efficacy and safety of Visonac PDT for acne (CTR), 1155, 1289, 1446
efficacy and safety study of 3.75% imiquimod cream following cryosurgery for AK, 1101
expanding the use of neurotoxins in facial aesthetics, s7 (January)
FDA reviewing safety of triclosan (PP), 874
FDA warns consumers in Puerto Rico of harmful bacteria in hand sanitizers (PP), 874
long-term efficacy and safety of topical PRK 124 lotion for rosacea, 647
long-term safety and efficacy of etanercept in psoriasis, 928
morning/morning regimen of tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for acne, 805
pediatric longitudinal evaluation of long-term safety of Protopic® for atopic dermatitis (CTR), 1446
pharmacokinetics and safety of luliconazole solution in distal subungual onychomycosis (CTR), 577, 1155
phase I study of BMS-833923 (XL139) in advanced or metastatic cancer (CTR), 883, 1033
safety and effectiveness of etanercept for lichen planus of oral mucosa or skin (CTR), 577, 883
safety and efficacy of abatacept for chronic urticaria after inadequate response to antihistamine therapy (CTR), 82, 1155
safety and efficacy of BFH772 in psoriasis patients

(CTR), 187, 425
safety and efficacy of CEM-102 versus linezolid in bacterial skin infections (CTR), 1538
safety and efficacy of clindamycin and tretinoin gel for rosacea (CTR), 187, 285, 425, 1033, 1538
safety and efficacy of etanercept for discoid lupus erythematosus (CTR), 1538
safety and efficacy of EXC 001 to improve appearance of scars from prior breast surgery (CTR), 727
safety and efficacy of IDP-107 in patients with acne vulgaris (CTR), 1446
safety and efficacy of oral nalfurafine HCl (AC-820) in subjects on hemodialysis with uremic pruritus (CTR), 82
safety and efficacy of tazarotene cream and adapalene gel in facial acne vulgaris, 549
safety and efficacy of tazarotene foam 0.1% in subjects with facial acne (CTR), 187, 425, 1446
safety and efficacy of topical 4% lidocaine gel in unique drug delivery system, 1500
safety and efficacy of topical IDP-108 versus vehicle in onychomycosis (CTR), 285, 577, 1538
safety and efficacy of ustekinumab in psoriatic arthritis patients who have prior exposure to anti-TNF agents (CTR), 1155
safety and HPA axis effects of two-compound ointment containing calcipotriene/betamethasone dipropionate for psoriasis, 969
safety and pharmacokinetics of famciclovir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 285
safety and pharmacokinetics of new formulation of bimatoprost in alopecia (CTR), 1446
safety, local tolerability, pharmacokinetics, and pharmacodynamics of LDE225 on sporadic superficial skin BCC (CTR), 285, 883, 1033
safety of dapsona in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients, 532
safety of teplizumab (MGA031) in subjects with moderate or more severe psoriasis (CTR), 82, 187, 425, 577
safety of topical doxycycline gel for adult diabetic lower extremity ulcers (CTR), 96
safety study of AMG 157 in healthy subjects and subjects with atopic dermatitis (CTR), 883, 1033, 1155, 1446
safety study of clinical and immune effects of phosphodiesterase-4 inhibitor in cutaneous lupus (CTR), 1538
tolerability and efficacy of novel formulation in treatment of melasma, 215
Sarcoidosis, thalidomide and analogues for, 814
Scalp lesions
flexible scalpels for minimally invasive and minimally scarring surgery for large scalp tumors, 1268
psoriasis, 912, s101 (August)
therapeutic shampoos for targeting symptoms of inflammatory scalp disorders, 41
utilization of a new tissue expander in closure of large Mohs surgical defect (CR), 149
Scalpel
flexible, for minimally invasive and minimally scarring surgery for large scalp tumors, 1268 modified, in hair restoration, 1266
Scars/scarring
ablative fractional treatment of mature thermal burn scars (CR), 389
appearance of burn scar after CO2 fractional laser treatment (CTR), 727
collagen-glycosaminoglycan copolymer for severe chest keloids, 542

correction of atrophic acne scars with Artefill®, 1062
effects of fractional carbon dioxide laser treatment prior to wound closure (CTR), 1155
effects of pulsed-dye laser on scar formation (CTR), 727, 1155
efficacy of spray silicone in alteration of burn scar (CTR), 727
evaluation of a liquid silicone gel on scar appearance after excisional surgery (CR), 856
evidence-based appraisal of lasers for scars, 1355
fractional photothermolysis for depressed alar scar following Mohs micrographic surgery (CR), 66
laser treatment for fresh surgical scars and mature scars (CTR), 727, 1155
medical and surgical management of keloids, 1249
Nd:YAG laser for acne keloidalis nuchae (CTR), 577
safety and efficacy of EXC 001 to improve appearance of scars from prior breast surgery (CTR), 727
single-spot, 2940-nm Er:YAG dual-mode laser treatment of facial acne scars, 1341
tolerability and efficacy of two topical therapies for keloids and hypertrophic scars, 514
treatment of burn scar with CO2 fractional laser (CR), 173
treatment of facial atrophic scars with Esthélic, 1507
treatment of surgical scars with pulsed dye laser (CTR), 727
ultrapulsed fractional CO2 laser for post-traumatic and pathological scars, 1328
Scleroderma
imatinib in (PP), 80
localized, treatment of, 1213
Scleromyxedema, IV immunoglobulin therapy for (CR), 263
Sclerotherapy, FDA approval of polidocanol for (NVR), 871
Sculptra®. See Poly-L-lactic acid
Sebaceous hyperplasia, isotretinoin as monotherapy for (CR), 699
Seborrheic dermatitis, therapeutic shampoos for targeting symptoms of inflammatory scalp disorders, 41
Sertaconazole nitrate cream, for itching (PP), 80
Sézary syndrome. See Mycosis fungoides/Sézary syndrome
Shampoos, therapeutic, for targeting symptoms of inflammatory scalp disorders, 41
Sickle cell ulcers, arginine butyrate plus standard local therapy in patients with (CTR), 1289
Siddha medicine, for cancer-related alopecia, 537
Silicone
efficacy of spray silicone in alteration of burn scar (CTR), 727
evaluation of a liquid silicone gel on scar appearance after excisional surgery (CR), 856
fillers for facial shaping, s129 (August)
histopathologic identification of dermal filler agents, 1072
hydrocortisone, silicone and vitamin E lotion for keloids and hypertrophic scars, 514
Simvastatin, hair growth in patients with alopecia areata totalis after treatment with ezetimibe and (CR), 62
Sirolimus, drug-associated acne and acneiform eruptions, 627
Skin cancer
ALA-PDT versus vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid

- organ transplant recipients (CTR), 82
- alemtuzumab followed by peripheral stem cell transplantation in advanced mycosis fungoides/Sézary syndrome (CTR), 888
- bevacizumab for angiosarcoma (CTR), 285
- BMS-833923 (XL139) in advanced or metastatic cancer (CTR), 883, 1033
- celecoxib inhibition of genetic BCC (PP), 418
- Charcot-Marie-Tooth disease and multiple malignant melanomas (CR), 164
- complete lymph node dissection or observation in treating patients with localized melanoma and sentinel node metastasis (CTR), 727
- correlation between skin carotenoid levels and previous history of (CTR), 1289
- CTLA4-induced splenomegaly and literature review of autoimmune complications of therapy (CR), 1432
- dasatinib for unresectable or metastatic SCC (CTR), 285
- dasatinib for unresectable or metastatic SCC or RAI stage 0–1 chronic lymphocytic leukemia (CTR), 883
- dermoscopy impact on skin cancer diagnostics, 129
- development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome (CR), 1014
- discussing sentinel lymph node biopsy with melanoma patients, 790
- efficacy and safety of GDC-0449 in patients with advanced BCC (CTR), 82, 285
- efficacy of itraconazole in BCC (CTR), 883, 1033
- efficacy of PDT for recurrent SCC and BCC, 122
- electrodesiccation and curettage versus excision for SCC, 773
- electronic brachytherapy for non-melanoma skin cancer (CTR), 1033
- erlotinib and radiotherapy for cutaneous SCC (CTR), 82, 285
- erlotinib in women with SCC of vulva (CTR), 1289
- erlotinib prior to surgery or radiation in patients with SCC (CTR), 883, 1289
- flexible scalpel for minimally invasive and minimally scarring surgery for large scalp tumors, 1268
- gemcitabine and docetaxel with or without bevacizumab in leiomyosarcoma, malignant fibrous histiocytoma and angiosarcoma (CTR), 285
- GSK2132231A antigen-specific immunotherapeutic in patients with inoperable metastatic cutaneous melanoma (CTR), 727, 1289
- human monoclonal antibody zanolimumab to treat mycosis fungoides/Sézary syndrome (CTR), 888
- immunostains used in Mohs surgery, 760
- intralesional interferon alfa-2b for BCC of nasal pyramid, 381
- ipilimumab for metastatic melanoma (PP), 1160
- iron overload and (NVR), 719
- Istodax for cutaneous T-cell lymphoma (PP), 183
- keratoacanthomas, 117
- lenalidomide for mycosis fungoides/Sézary syndrome (CTR), 888
- MAGE-A3 antigen-specific cancer immunotherapeutic in patients with progressive metastatic cutaneous melanoma (CTR), 1289
- management of Merkel cell carcinoma with emphasis on small primary tumors, 105
- Merkel cell carcinoma, 779
- Mohs surgery for melanoma in situ, 786
- multiple skin cancers in a patient on combination immunosuppressive therapy for Behçet's disease (CR), 152
- multi-wavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented skin lesions (CTR), 1033
- N-acetylcysteine to reduce melanoma risk (PP), 183
- new melanoma staging system (NVR), 1029
- nilotinib in TKI resistant or intolerant patients with metastatic mucosal, acral, or chronically sundamaged melanoma (CTR), 883
- osteoinvasive subungual melanoma (CR), 159
- patient with nevoid BCC syndrome treated successfully with PDT (CR), 167
- PDT to treat actinic damage in patients with SCC of lip (CTR), 82, 1289
- PDT using ALA in treating patients with (CTR), 85
- PEG-interferon alfa-2b and UV light therapy in mycosis fungoides/Sézary syndrome (CTR), 888
- pegylated interferon for children with high-risk melanoma (CTR), 727, 1289
- population education in prevention: from childhood to adulthood, 112
- in pregnancy (NVR), 1297
- promising results of metastatic melanoma phase 1 trial of PLX4032 (PP), 1455
- rapid wound re-epithelialization and BCC clearance after Mohs micrographic surgery with postoperative PDT (CR), 143
- rapid wound re-epithelialization and BCC clearance after Mohs surgery with postoperative PDT (RR), 878
- role of phototherapy in cutaneous T-cell lymphoma, 764
- maintenance phototherapy, 800
- safety, local tolerability, pharmacokinetics, and pharmacodynamics of LDE225 on sporadic superficial skin BCC (CTR), 285, 883, 1033
- successful treatment of cutaneous T-cell lymphoma with topical 5-fluorouracil (CR), 1017
- systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients, 753
- TH17 in regression of metastatic melanoma to topical diphenylprone, 1368
- thalidomide and analogues for, 814
- trial of Dermacorder for detecting malignant skin lesions (CTR), 883
- UV light exposure and immunosuppression in cutaneous melanoma (CTR), 1289
- vaccine therapy in stage IV cutaneous melanoma (CTR), 1289
- ZD1839 for recurrent or metastatic SCC of skin (CTR), 883
- Skin Cancer Foundation**, Iredale Mineral Cosmetics receives Seal of Recommendation from, 572
- Skin resurfacing**
- Groove Optic™ for Lux2940™ for (PP), 183
- treatment of CO2 laser induced hypopigmentation with ablative fractionated laser resurfacing (CR), 1420
- Sodium sulfacetamide 10%, sulfur emollient 5% foam**, in treatment of inflammatory facial dermatoses (BC), 234
- Soft tissue augmentation**
- attaining predictable aesthetic results with dermal fillers, 458
- Belotero dermal filler close to FDA approval (PP), 1455
- calcium hydroxyapatite in nonsurgical aesthetic rejuvenation, 446
- Emervel Classic Lidocaine versus Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
- Emervel Deep Lidocaine versus Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
- fillers for facial shaping, s129 (August)
- hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for aesthetic rejuvenation therapy, 1135
- injection techniques for revolumization of perioral region with hyaluronic acid, 367
- monophasic, cohesive-polydensified-matrix crosslinking-technology-based HA filler for facial lipotrophy in HIV-infected patients (CR), 690
- pain with Radiesse® with lidocaine for nasolabial folds (CTR), 577
- Restylane and Perlane in correction of peri-oral wrinkles (CTR), 187
- treatment of facial atrophic scars with Esthéélis, 1507
- treatment of forehead/glabellar rhytide complex with combination botulinum toxin A and hyaluronic acid versus botulinum toxin injection alone (CTR), 1538
- use of injectable poly-L-lactic acid in people of color, 451
- Sorafenib**
- annular leukocytoclastic vasculitis associated with (CR), 697
- psoriasiform eruption induced by, in patient with metastatic thyroid carcinoma (CR), 169
- Soy**, cosmeceuticals in clinical practice, s62 (May)
- Spirolactone**
- spironolactone pills versus minoxidil lotion in female pattern hair loss (CTR), 577
- in treatment of acne (NVR), 546
- Squamous cell carcinoma (SCC)**
- dasatinib for unresectable or metastatic SCC (CTR), 285
- dasatinib for unresectable or metastatic SCC or RAI stage 0–1 chronic lymphocytic leukemia (CTR), 883
- efficacy of PDT for recurrent SCC and BCC, 122
- electrodesiccation and curettage versus excision for, 773
- electronic brachytherapy for non-melanoma skin cancer (CTR), 1033
- erlotinib and radiotherapy for cutaneous SCC (CTR), 82, 285
- erlotinib in women with SCC of vulva (CTR), 1289
- erlotinib prior to surgery or radiation in patients with (CTR), 883, 1289
- flexible scalpel for minimally invasive and minimally scarring surgery for large scalp tumors, 1268
- multi-wavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented skin lesions (CTR), 1033
- PDT to treat actinic damage in patients with SCC of lip (CTR), 82, 1289
- ZD1839 for recurrent or metastatic SCC of skin (CTR), 883
- SRT2104**, clinical activity, safety, and tolerability in subjects with psoriasis (CTR), 1446
- Staphylococcus aureus infection**
- methicillin-resistant (MRSA)
- new antibiotics for (NVR), 77
- oregano-based ointment with antimicrobial activity against, 377
- retapamulin versus linezolid in treatment of SITL and impetigo due to (CTR), 86, 1538
- Sanofi Pasteur and Syntiron development of MRSA vaccine (PP), 282
- using off-patent antibiotics for (CTR), 1538
- retapamulin and antimicrobial resistance of, 1198
- Statins in skin**, 921
- Stelara**. See Ustekinumab

Stem cell transplantation

alemtuzumab followed by peripheral stem cell transplantation in advanced mycosis fungoides/Sézary syndrome (CTR), 888
 combination stem cell therapy for treatment of severe leg ischemia (CTR), 1289
 hematopoietic stem cell support in patients with autoimmune bullous skin disorders (CTR), 1289
 safety of adult stem cells to treat patients with severe leg artery disease (CTR), 1289
 Soligenix study of orBec® for prevention of GVHD after (PP), 1033

Steroid sulfatase gene deletion, in Egyptian males with X-linked ichthyosis, 1192

Stevens-Johnson syndrome

(NVR), 1545
 bupropion-induced, with acute psoriatic exacerbation (CR), 1010

fluconazole-associated, 1272

Stress, relaxation strategies for patients during dermatologic surgery, 795

Stretch marks

first fractional laser FDA cleared for (PP), 418
 Mederma® for (PP), 418

Sulfonamides, safety of dapsone in patients with allergies to, 532

Sulfur, multifunctionality of 10% sodium sulfacetamide, 5% sulfur emollient foam in treatment of inflammatory facial dermatoses (BC), 234

Sunburn, iron overload and (NVR), 719

Sunscreens

dermal effects of nanoparticles, 475
 Iredale Mineral Cosmetics receives Seal of Recommendation from Skin Cancer Foundation, 572
 oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11
 update: controversies, what's safe, what's next (NVR), 1446

T**T cells**

CTLA4-induced splenomegaly and literature review of autoimmune complications of therapy (CR), 1432

and dendritic cells in immunotherapy, 1383
 role of complement in dendritic cell control of subsets of (editorial), 1364

TH17 in regression of metastatic melanoma to topical diphencyprone, 1368

T4N5 liposome lotion, reduced number of AK with, 1519

Tacrolimus

cost-effectiveness versus pimecrolimus cream for atopic dermatitis, 372

drug-associated acne and acneiform eruptions, 627

for pruritus in atopic dermatitis, 488

in treatment of morphea, 1213

Tamiflu®. See Oseltamivir

Tanning beds, FDA recommendations for use (PP), 874

Tarceva®. See Erlotinib

Tattoo treatment

alexandrite laser with two Nd:YAG laser handpieces pumped by alexandrite treatment beam for, 1333

"tattoo blow-out" pigment spread treated with QS-Nd:YAG laser (CR), 1429

Taxotere, eruption secondary to (CR), 1534

Tazarotene

safety and efficacy of tazarotene cream and adapalene gel in facial acne vulgaris, 549

safety and efficacy of tazarotene foam in subjects with facial acne (CTR), 187, 425, 1446
 topical, rapid improvement in digital ischemia and acral contracture in colloidion baby treated with (CR), 713

TDT 067, in onychomycosis (CTR), 1538

Tea polyphenols, oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11

Telavancin (NVR), 76

Temozolomide, urticarial hypersensitivity reaction caused by (CR), 1142

TempASSURE device (PP), 418

Teplizumab (MGA031), safety in subjects with moderate or more severe psoriasis (CTR), 82, 187, 425, 577

Terbinafine gel, efficacy and safety of iontophoretic application in onychomycosis (CTR), 577, 1155

Tetraethylthiuram disulfide, drug-associated acne and acneiform eruptions, 627

Thalidomide

and analogues for immunomodulation of inflammatory and neoplastic disorders, 814

effect on nitric oxide production in RAW 264.7 cells, 330

Thymosin beta-4, effect on wound healing in epidermolysis bullosa (CTR), 727

Tigecycline

(NVR), 76

increased mortality risk linked to (PP), 1455

Tinea pedis, Ertaczo® relieves itching (PP), 80

Tissue expanders, utilization in closure of large Mohs surgical defect (CR), 149

Tissue fillers

attaining predictable aesthetic results with, 458
 Belotero dermal filler close to FDA approval (PP), 1455

calcium hydroxyapatite in nonsurgical aesthetic rejuvenation, 446

correction of atrophic acne scars with Artefill®, 1062

effect of lidocaine when mixed with large gel particle hyaluronic acid filler on tolerability and longevity, 1097

Emervel Classic Lidocaine versus Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538

Emervel Deep Lidocaine versus Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538

for facial shaping, s129 (August)

FDA approves Juvéderm® XC with lidocaine (PP), 418

histopathologic identification of, 1072

hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for aesthetic rejuvenation therapy, 1135

injection techniques for revolumization of perioral region with hyaluronic acid, 367

lip tenting technique, 559

localization and histology of injected hyaluronic acid in excised nasolabial fold tissue (CR), 399

minimally invasive techniques for periorbital rejuvenation, s118 (August)

monophasic, cohesive-polydensified-matrix crosslinking-technology-based HA filler for facial lipatrophy in HIV-infected patients (CR), 690

pain with Radiesse® with lidocaine for nasolabial folds (CTR), 577

Restylane and Perlane in correction of peri-oral wrinkles (CTR), 187

tolerability and efficacy of novel formulation of hyaluronic acid in treatment of melasma, 215

treatment of facial atrophic scars with Esthéélis, 1507

treatment of forehead/glabellar rhytide complex with combination botulinum toxin A and hyaluronic acid versus botulinum toxin injection alone (CTR), 1538

use of injectable poly-L-lactic acid in people of color, 451

Titanium dioxide, sunscreen update: controversies, what's safe, what's next (NVR), 1446

Topically dissolved oxygen (TDO), to ameliorate signs of photodamage (CTR), 187, 425

Torezolid phosphate, phase 3 study of (PP), 1160

Toxic epidermal necrolysis

(NVR), 1545

due to cardiac catheterization dye (CR), 837

TR-701, for bacterial skin infections (CTR), 1538

Training, identifying the right dermatologic surgery fellowship for you (RR), 421

Transplant recipients, ALA-PDT versus vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 82

Travatan. See Travoprost

Travoprost, effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 1289

Tretinoin

acne relapse rate of oral minocycline versus oral minocycline combined with topical tretinoin, followed by topical tretinoin alone (CTR), 577, 727

antimicrobial efficacy of benzoyl peroxide/clindamycin phosphate gel versus clindamycin phosphate/tretinoin gel for acne vulgaris, 131

Atralin gel for rosacea (CTR), 1033, 1538

irritation potential of tretinoin gel microsphere pump versus adapalene plus benzoyl peroxide gel, 998

morning/morning regimen of tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for acne, 805

optimizing acne therapy with unique vehicles, s53 (May)

safety and efficacy of clindamycin and tretinoin gel for rosacea (CTR), 187, 285, 425, 1033, 1538

topical tretinoin gel and acne in preadolescents (PP), 1033

treating photodamage of décolletage area with novel copper zinc malonate complex plus hydroquinone and, 220

Triamcinolone, efficacy of triamcinolone 0.1% cream occluded with hydrogel patch versus triamcinolone 0.1% cream without occlusion for eczema (CTR), 883

Trichloroacetic acid, utilizing combination or sequential treatment with 5-fluorouracil cream and destructive treatments (CR), 864

Triclosan, FDA reviewing safety of antibacterial soap ingredient (PP), 874

Trimethoprim-sulfamethoxazole, using off-patent antibiotics for MRSA (CTR), 1538

Tumor necrosis factor - effect of thalidomide on nitric oxide production in RAW 264.7 cells, 330

Tygacil. See Tigecycline

U

U0279, and injectable biologic combination therapy for psoriasis (CTR), 285

Ulcers

arginine butyrate plus standard local therapy in patients with refractory sickle cell ulcers (CTR), 1289

drug therapy for Buruli ulcer, 341

FDA clearance of V.A.C. therapy for venous insufficiency ulcers (PP), 1160

oxandrolone in treatment of decubitus ulcers

(CR), 711
 prompt biological therapy speeds diabetic foot ulcer healing (PP), 1455
 safety of topical doxycycline gel for adult diabetic lower extremity ulcers (CTR), 96

Ultrasonography
 FDA approves Ulthera's ultrasound product (PP), 282
 high resolution ultrasound helps in diagnosis of blue skin lesions (PP), 1160

Ultravate® ointment. See Halobetasol propionate ointment

Ultraviolet (UV) radiation exposure
 and immunosuppression in cutaneous melanoma (CTR), 1289
 PEG-interferon alfa-2b and UV light therapy in mycosis fungoides/Sézary syndrome (CTR), 888
 proposed indoor tanning tax (PP), 282
 role of phototherapy in cutaneous T-cell lymphoma, 764
 maintenance phototherapy, 800
 usefulness of narrowband UVB as monotherapy for chronic plaque psoriasis, 989

Urticaria
 chronic
 etanercept for (CTR), 1155
 hydroxychloroquine efficacy in (CTR), 1155
 safety and efficacy of abatacept after inadequate response to antihistamine therapy (CTR), 82, 1155
 second-generation antihistamines for, 503
 hypersensitivity reaction caused by temozolomide (CR), 1142
 in pregnancy (NVR), 1297

Ustekinumab
 effects on primate/human antigen-recall and humoral immune response functions, 677
 versus etanercept for psoriasis (PP), 572
 how and when to use biologics in psoriasis, s106 (August)
 for psoriasis and psoriatic arthritis, 947
 safety and efficacy in psoriatic arthritis patients who have prior exposure to anti-TNF agents (CTR), 1155
 use in pediatric psoriasis, 975

V

Vaccines
 FDA approves new indications for HPV vaccine (PP), 80
 Sanofi Pasteur and Syntiron development of MRSA vaccine (PP), 282
 vaccine therapy in stage IV cutaneous melanoma (CTR), 1289

Valacyclovir
 versus EPB-348 for herpes zoster (CTR), 1033
 versus FV-100 for herpes zoster (CTR), 1033
 Mylan receives approval for generic (PP), 1033

Valproate, drug-associated acne and acneiform eruptions, 627

Vasculature
 annular leukocytoclastic vasculitis associated with sorafenib (CR), 697
 combination stem cell therapy for treatment of severe leg ischemia (CTR), 1289
 FDA approves polidocanol for small varicose veins (PP), 723
 iron overload and chronic venous disease (NVR), 719
 nanotechnology as topical therapeutic strategy for vascular dysfunction (RR), 574
 safety of adult stem cells to treat patients with severe leg artery disease (CTR), 1289

VB-201, for psoriasis (CTR), 1033, 1446

Vectibix®. See Panitumumab

VECTRA M3 facial imaging system (PP), 418

Venous insufficiency ulcers, FDA clearance of V.A.C. therapy for (PP), 1160

Verapamil, medical and surgical management of keloids, 1249

Vericose veins, FDA approval of polidocanol for sclerotherapy (NVR), 871

Vibativ. See Telavancin

Vibrio vulnificus infection, drug therapy for, 341

Vincristine, for infantile hemangiomas (NVR), 176

Vitamin A, in treatment of morphea, 1213

Vitamin B6, drug-associated acne and acneiform eruptions, 627

Vitamin B12
 drug-associated acne and acneiform eruptions, 627
 topical, for childhood atopic dermatitis (CTR), 1155, 1446

Vitamin C
 cosmeceuticals in clinical practice, s62 (May)
 oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11

Vitamin D analogues, in treatment of morphea, 1213

Vitamin E
 cosmeceuticals in clinical practice, s62 (May)
 hydrocortisone, silicone and vitamin E lotion for keloids and hypertrophic scars, 514
 oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11

Vitiligo, failure of botulinum toxin treatment for, 1092

Vivité Skin Care System, controlled multi-center study evaluating the efficacy for photoaging of face, eye and mouth, 22

Voriconazole, in X-linked chronic granulomatous disease, photosensitivity/photoaging induced by (CR), 562

Vulva, erlotinib in women with SCC of (CTR), 1289

W

Warfarin-induced skin necrosis (CR), 859

Warts, FDA approves new indications for HPV vaccine (PP), 80

White petrolatum, drug-associated acne and acneiform eruptions, 627

Wong type dermatomyositis, 1475

Wound dressings, exSALT SD7™ compared to Xeroform® petrolatum dressing for management of partial thickness donor sites (CTR), 727

Wound healing
 assessment of mechanisms of improved wound healing (CTR), 727
 beta-blocker for chronic wound healing (CTR), 727
 comparative efficacy and safety of topical hemostatic powder and sterile compressed foam sponge in second intention healing after Mohs micrographic surgery, 137
 effect of thymosin beta-4 on wound healing in epidermolysis bullosa (CTR), 727
 efficacy of hexapeptide-7 on menopausal skin, 49
 isotretinoin-induced effects of mast cells on, 1207
 rapid wound re-epithelialization and BCC clearance after Mohs micrographic surgery with postoperative PDT (CR), 143
 rapid wound re-epithelialization and BCC clearance after Mohs surgery with postoperative PDT (RR), 878
 safety of topical doxycycline gel for adult diabetic lower extremity ulcers (CTR), 96
 vertical undermining for closure of partial thickness surgical defects, 674

Wrinkles

comparison of RevLite Electro-optic Q-switched neodymium-doped yttrium aluminium garnet laser to a fractionated laser system (CTR), 82, 187, 425, 1033, 1155, 1289
 controlled multi-center study evaluating the efficacy of Vivité Skin Care for photoaging of face, eye and mouth, 22
 Emervel Classic Lidocaine versus Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
 Emervel Deep Lidocaine versus Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
 FDA approval of eMatrix device for (PP), 572
 novel sonic infusion system for periorbital rhytides, 1121
 prospective study of improvement in periorbital wrinkles and eyebrow elevation with novel fractional CO2 laser—the fractional eyelift, 16
 Restylane and Perlane in correction of peri-oral wrinkles (CTR), 187
 treatment of forehead/glabellar rhytide complex with combination botulinum toxin A and hyaluronic acid versus botulinum toxin injection alone (CTR), 1538

X

Xalatan. See Latanoprost

Xeomin®. See Incobotulinumtoxin A

Xeroform® petrolatum dressing, compared to exSALT SD7™ for management of partial thickness donor sites (CTR), 727

X-linked chronic granulomatous disease, voriconazole-induced photosensitivity/photoaging in (CR), 562

X-linked ichthyosis, steroid sulfatase gene deletion in Egyptian males with, 1192

Xyzal. See Levocetirizine

Z

Zanolimumab, to treat mycosis fungoides/Sézary syndrome (CTR), 888

ZD1839. See Gefitinib

Zeftera. See Ceftriaxone

Zerona, FDA-approved for body slimming (PP), 1455

Zinc oxide, sunscreen update: controversies, what's safe, what's next (NVR), 1446

Zyclara™. See Imiquimod cream

